

Curriculum Vitae

Melvin Lee Kiang CHUA

MBBS, FRCR, PhD, FAMS, FASCO

as of 4 July 2025

CURRENT APPOINTMENTS

- (2021-Present) Head, Department of Head and Neck and Thoracic Radiation Oncology
- (2018-Present) Senior Consultant, Division of Radiation Oncology, National Cancer Centre Singapore (NCCS)
- (2014-Present) Principal Investigator, Precision Radiotherapeutics Oncology Programme, Division of Medical Sciences
- (2021-Present) Director, Data and Computational Science Core, NCCS
- (2022-Present) Lead Theme Principal Investigator, National Medical Research Council Open-Fund Large Collaborative Programme for Nasopharyngeal Carcinoma
- (2020-Present) Associate Professor (on Tenure), Duke-NUS Medical School
- (2019-Present) Visiting Professor, Zhongnan Hospital of Wuhan University

SHORT BIOGRAPHY

I am a Clinician-Scientist with a joint appointment at the National Cancer Centre Singapore (NCCS) and the Duke-NUS Medical School. I am currently an Associate Professor (On Tenure) of Duke-NUS Medical School, Singapore; Visiting Professor of the Zhongnan Hospital of Wuhan University, China. I am also a Principal Investigator of the Precision Radiotherapeutics and Oncology Programme (PROP). Additionally, I am the Head of Department and Senior Consultant for the Department of Head and Neck and Thoracic Radiation Oncology, and Director of the Data and Computational Science Hub at the NCCS.

Our work is supported by several National grants including: (1) the NMRC CSA (Investigator-category); (2) the National Research Foundation Competitive Research Programme (NRF-CRP); (3) the Ministry of Education Tier 3 Grant; (4) the NMRC Open Fund Large Collaborative Grant (OF-LCG); and (5) the NMRC Centre Grant. Additionally, we are supported by large philanthropic donations, notably from the Goh Foundation to Proton Therapy Research, the Tibore Foundation to the Kua Hong Pak Head and Neck Cancer Research Programme, and the Singapore Rubber Miller Association to the Cancer and Data Science Programme, along with several industry support (BeiGene, Varian, MiRXES, ImmunoScape, etc.). **Collectively, as PI and Theme PI, I have secured >25M SGD of research dollars**, which support our 2 key programmes:

- (1) A comprehensive nasopharyngeal carcinoma (NPC) and prostate cancer (PCa) clinical and translational research programme that leverages on innovative designs of phase II-III trials, a multi-dimensional, deeply-annotated clinical-molecular database, coupled with broad-scale computational genomics approaches for biomarker discoveries.
- (2) A translational radiation research programme that leverages on bench-to-bedside expertise to understanding the mechanistic pathways of radiation resistance (RR), and to develop new treatment regimens to target these molecular vulnerabilities.

My key accomplishments include: (1) being involved in the ASCO-CSCO international guidelines on the treatment of locoregionally-advanced NPC (published in **Journal of Clinical Oncology, IF 50.717**); (2) Co-Lead Investigator of the randomised controlled trial of induction gemcitabine-cisplatin in high-risk locoregionally-advanced NPC (published in **the New England Journal of Medicine, IF 176.1**); (3) Co-Lead Investigator of the randomised controlled trial of consolidation radiotherapy in patients with metastatic NPC who manifest a good response to palliative chemotherapy (published in **JAMA Oncology, IF 33.1**); (4) Co-Lead Investigator of the randomised controlled trial of adjuvant capecitabine following chemoradiotherapy in high-risk locoregionally-advanced NPC (published in **JAMA Oncology, IF 33.1**). Currently, I co-lead the **Singapore NPC Large Collaborative Grant (funding quantum 10M SGD)**, where I lead a platform trial – RIBBON: tReatment Individualisation By eBv stratificatiON in Locally Advanced nasopharyngeal carcinoma: A multi-arm platform study – for locoregionally advanced NPC and recurrent-metastatic NPC. I am also a Co-Lead Investigator of 2 other phase II and phase III trials in NPC (**REACT-IrNPC, NCT04448522**; **EP-STAR, NCT04072107**).

I am extensively involved in the leadership and membership of several committees on Head and Neck Cancer; (1) I am on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network; (2) Board representative for Singapore for the Head Neck Cancer International Group (HNCIG); (3) **Chair of the Clinical Trials Scientific Committee of HNCIG**; (4) **Chair of the NPC Expert Panel for the AJCC and UICC Staging 9th version**; (5) **UICC Representative AJCC Head and Neck Working Group for Nasopharynx Malignancy**; (6) Member of the ESTRO guidelines committee for the recommendations of post-operative radiotherapy in oral cavity cancers. My other academic activities include my present role as the Editor-in-Chief, Annals of Nasopharynx Cancer, Associate Editor of BMJ Oncology, BMC Medicine, and Journal of the National Cancer Centre, and my previous role as the Associate Senior Editor for the Head and Neck Cancer Section of the International Journal of Radiation Oncology Biology Physics – Official journal of the American Society of Radiation Oncology.

I am also an active volunteer for the American Society of Clinical Oncology (ASCO); I had previously served on the International Education Steering Group, Mentor on the inaugural APAC ASCO Leadership Development Program, and **past Council Member and Chair of the ASCO APAC Regional Council (term ended on 1 Jun 2024)**. I am also currently the **Program Chair for the ASCO Breakthrough Meeting 2024**. Additionally, I am also the **Commissioner**

representative for Singapore on the Lancet Oncology Commission on Cancer in the Commonwealth, and in 2025, I was appointed as the Commissioner for the ICRU – The International Commission for Radiation Units and Measurements.

I am also an ad hoc advisor to several local and global companies, including Merck, MSD, BeiGene, Bicara Therapeutics, Pfizer, Janssen, Varian, and ImmunoScape; **Of note, I am on the Global Advisory Team to advise MSD, Bicara Therapeutic, and Pfizer on their Head and Neck Cancer strategy and therapeutic portfolio.** I am also a Co-Founder of an antibody-based lateral flow diagnostic kit that has spun-off to a biotechnology company – Digital Life Line, for which I currently serve on the Board of Directors.

I have published over 210 peer-reviewed papers, with a H-index of 45 (>12,000 citations); **I am the Lead Author of the Nasopharynx Cancer Chapter of the 12th edition of the Cancer: Principles & Practice of Oncology – the most widely-used oncology textbook worldwide, as well as other highly cited articles in the New England Journal of Medicine, Lancet, Nature, Cell, Journal of Clinical Oncology and JAMA Oncology. Consequently, I am listed as the World’s Top 2% Most Cited Scientists in 2023 and 2024.** For my work, I have received numerous honours, including the SingHealth Excellence Distinguished Researcher Award, Conquer Cancer Foundation ASCO Merit Awards, NMRC Clinician-Scientist Award (Investigator), Fellow of the Royal College of Radiologists, Fellow of the Academy of Medicine Singapore (FAMS), and **Fellow of the American Society of Clinical Oncology (FASCO; first Singaporean National to be inducted for class of 2025).**

EDUCATION & TRAINING

Degrees, Board Certification

2021	Fellow of the Academy of Medicine Singapore (FAMS), The College of Radiation Oncology and Clinician Scientists, Singapore
2013	Doctor of Philosophy (PhD), University College London, UK
2013	Fellow of the Royal College of Radiologists (FRCR <i>for Clinical Oncology</i>), The Royal College of Radiologists, UK
2002	Bachelor for Medicine and Surgery (MBBS), National University of Singapore

Undergraduate Education

1997-2002	Yong Loo Lin School of Medicine, National University of Singapore
-----------	---

Post-graduate, Research, and Specialty Training

2022, Aug-Dec	SingHealth and Singapore Management University Graduate Diploma of Healthcare Management <i>Summa Cum Lauda (GPA 3.98)</i>
2021, Jun	INSEAD Executive Course on Leading Business Transformation in Asia
2019, Jun	SingHealth and Singapore Management University Organisational Leadership and Executive Development Programme
2015-2016	Genitourinary Oncology Clinical Research Fellowship, Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto. <i>Supervisor: Prof Robert Bristow</i>
2015, Jul	Molecular Biology in Clinical Oncology Workshop, American Association of Cancer Research, Snowmass, CO
2013, Jan-Sep	Honorary Clinical Observer, Mount Vernon Cancer Centre
2009-2013	Doctor of Philosophy, University College London

Project Title: DNA Damage Responses in relation to Late Normal Tissue Effects following Radiotherapy for Early Breast Cancer

Supervisors: Prof John Yarnold (ICR), Prof Susan Short (Leeds), Prof Kai Rothkamm (Hamburg-Eppendorf)

2006-2009	Resident, Division of Radiation Oncology, National Cancer Centre Singapore (Chief Resident, 2008-2009)
2004-2006	Army Medical Officer, 4 th Singapore Armoured Brigade, Singapore Armed Forces (Mandatory 2-y National Service)
2004, Jan-Jun	Medical Officer, Department of Neonatology and Intensive Care, KK Children and Women's Hospital, SingHealth
2003, May-Dec	Medical Officer, Department of Anaesthesia and Intensive Care, Singapore General Hospital, SingHealth
2002-2003	House Officer, National Healthcare Group (4-mo rotations in General Surgery, Orthopaedic Surgery, Internal Medicine)

Awards

2025	Fellow of the American Society of Clinical Oncology (FASCO) – First Singaporean National to be inducted
2024	World's Top 2% Most Cited Scientists 2024
2023	World's Top 2% Most Cited Scientists 2023
2023	SingHealth Service Quality Star Award, Singapore
2021	SingHealth Excellence Award – Distinguished Researcher Award, Singapore
2021	National Medical Research Council Clinician-Scientist (Investigator) Award, Singapore
2020	MOH Health Manpower Development Plan Leadership Award (<i>INSEAD Leading Business Transformation in Asia</i>)
2018	National Medical Research Council Clinician-Scientist (Investigator) Award, Singapore
2017	Ferring Singapore Innovation Award 2017 (<i>only selected awardee for Urology</i>)
2017	ASCO Merit Award for 2017 ASCO GU symposium, Orlando
2016	ASCO Merit Award for 2016 ASCO Annual Meeting, Chicago
2015	Canadian Urologic Oncology Group (CUOG)-Sanofi Research Award
2014	National Medical Research Council Transition Award, Singapore
2013	Best Poster Award, EPR Biodose, Leiden
2013	ASCO Merit Award for 2013 ASCO Annual Meeting, Chicago
2011	Young Investigator Travel Award, 12 th Wolfsberg International Meeting on Molecular Radiation Biology/Oncology
2011	Association for Radiation Research Early Career Investigator Award, 14 th International Congress of Radiation Research, Warsaw
2011	World Scientist Forum International Awards Eminent Scientist of the Year 2011 for Radiotherapy Oncology, Asia
2008	Best Oral Scientific Paper, 14 th Asean Association of Radiology Meeting, Korea

PROFESSIONAL AFFILIATIONS

Professional Associations

2021-Present	Fellow, The College of Radiation Oncology and Clinician Scientists, Academy of Medicine, Singapore
2017-Present	Member, European Society of Medical Oncology
2015-Present	Member, American Association of Cancer Research
2014-Present	Member, Singapore Radiological Society
2014-Present	Member, Singapore Society of Oncology
2013-Present	Fellow, The Royal College of Radiologists
2012-Present	Member, American Society of Radiation Oncology
2012-Present	Member, American Society of Clinical Oncology
2009-Present	Member, British Institute of Radiology
2009-Present	Member, European Society of Radiotherapy and Oncology

Scientific Panels

2024	UICC Representative AJCC Head and Neck Working Group for Nasopharynx Malignancy
2023	Chair, NPC Expert Panel for AJCC Staging 9th version
2023	Chair, ASCO Breakthrough Meeting Program Planning Committees
2023	Member, ESTRO Guidelines Committee for Recommendations on Post-operative Radiotherapy in Oral Cavity Cancers
2022-Present	Chair, Head Neck Cancer International Group (HNCIG) Scientific Committee
2022	Chair-elect, ASCO Breakthrough Meeting Program Planning Committees
2022-Present	Honorary KOL, Thoracic and Head and Neck Tumour group, Singapore Translational Cancer Consortium (STCC)
2021-Present	Chair, HNCIG-Artificial Intelligence (HNCIG-AI) Scientific Committee
2020	ASCO-CSCO International Guidelines Committee in Nasopharyngeal Carcinoma
2020-Present	Elected Faculty, F1000 – Head and Neck Cancer Section
2019-Present	Member, Radiogenomics Consortium
2018-Present	Member, PRACTICAL Prostate Cancer Genomics Consortia

Administrative / Executive Roles

Local

2022-Present	Focus group member for Talent Development, Duke-NUS Academic Medical Council Research Masterplan
2021-Present	Member, NCCS IT Steering Committee
2021-Present	Director, Data and Computational Science Hub, NCCS
2021-Present	EXCO member, SingHealth Cluster Artificial Intelligence Program

2021-Present	Member, RIE2025 NMRC Transition Award Review Panel
2021-Present	Head, Department of Head and Neck and Thoracic Cancers, Division of Radiation Oncology, NCCS
2021-Present	Member, Singapore Society of Oncology-Cancer Immunotherapy Consortium Education Committee
2021-Present	Member, NCCS Division of Clinical Trials and Epidemiological Sciences Protocol Steering Committee
2020-Present	Co-Director, NCCS-SingHealth Tissue Repository
2019-Present	Co-Chair, NCCS Research Biosafety Committee
2018-Present	EXCO member, Singapore Society of Oncology
2018-Present	Member, NCCS Research Biosafety Committee
2018-Present	Member, Grant Monitoring Committee of NCCS Research Fund
2018	Co-Chair, NCCS Biennial Research Book Committee
2017-Present	Member, Clinical Service Line Discussion Group for Head and Neck, Genitourinary, and Nasopharynx Cancers, NCCS
2014-2015	EXCO member, Singapore Radiological Society

International

2025-Present	Commissioner, International Commission of Radiation Units and Measurements (ICRU)
2024-Present	Commissioner, The Lancet Oncology Commission on Cancer in the Commonwealth
2023-2024	Chair, ASCO Asia-Pacific Regional Council
2022-Present	Chair, Alice's Arc Scientific and Grants Review Committee
2021-Present	Member, Varian Therapy Advancement – Asia-Pacific Thought Leadership Council
2021-Present	International Advisory Panel, Fukushima Journal of Medical Science (FJMS)
2019-Present	Board Member, HNCIG
2019-2024	Member, ASCO Asia-Pacific Regional Council
2019-2020	Member, ASCO – International Education Steering Group (IESG)
2017-2020	Member, ASCO – Multidisciplinary Cancer Management Course (MCMC) Working Group
2016-Present	Trustee, Alice's Arc (Children's Cancer Charity, UK; Charity Commission No. 1164253)

Consultancy / Board of Directors

- ImmunoScape Pte Ltd
- Digital Life Line Pte Ltd
- PVMed

Advisory Boards

- AstraZeneca
- Astellas
- Bayer Pharma
- BeiGene
- Bicara Therapeutics

- Illumina
- Janssen Pharma
- Merck (MSD Oncology)
- Varian

ACADEMIC COMMITMENTS

External Faculty Appointments

- 2022-Present External assessor, University of Malaya Masters of Clinical Oncology Programme
- 2019-Present Visiting Professor, Zhongnan Hospital of Wuhan University

Journal Editorial Roles

- 2025-Present Honorary Advisor of the Hong Kong Journal of Radiology
- 2024-Present Associate Editor of the Nasopharynx Section of the Head and Neck Chapter for UICC TNM Classification of Malignant Tumours, 9th Ed
- 2023-Present Associate Editor, BMC Medicine
- 2023-Present Associate Editor, BMJ Oncology
- 2021-Present Editor, Journal of National Cancer Centre
- 2021-Present Editor, Therapeutic Advances in Medical Oncology
- 2018-2022 Associate Senior Editor, Head and Neck section – International Journal of Radiation, Oncology, Biology and Physics, Official journal of the American Society of Radiation Oncology (Red J)
- 2018-2022 Editor, Therapeutic Radiology and Oncology – Official journal of the Taiwan Society for Therapeutic Radiology and Oncology
- 2018-2022 Editor, Precision Cancer Medicine
- 2017-Present **Editor-in-Chief, Annals of Nasopharynx Cancer**
- 2016-2021 Editor, Chinese journal of Clinical Oncology
- 2016-2020 Associate Editor, British Journal of Radiology

Guest Editorial Roles

- 2017, Aug Special issue, Stereotactic Radiosurgery in Modern Precision Oncology, Chinese journal of Clinical Oncology
- 2016, Apr Special issue, Nasopharyngeal Carcinoma, Chinese journal of Clinical Oncology

Peer Reviewer

Editor

- BMC Medicine
- BMJ Oncology
- Annals of Nasopharynx Cancer
- Therapeutic Advances of Medical Oncology
- Journal of National Cancer Centre

Ad-hoc reviewer (Selected; ≥1 article/year)

(IF >20.0)

- New England Journal of Medicine
- The Lancet
- The British Medical Journal
- Journal of Clinical Oncology
- Lancet Oncology
- Cancer Cell – Cell Press
- Med – Cell Press
- Annals of Oncology
- Signal Transduction and Targeted Therapy

(IF >10.0)

- Cell Reports Medicine
- Cell Death Differentiation
- Clinical Cancer Research
- Cancer Communications
- Cancer Treatment Reviews
- EBioMedicine – Lancet journals
- EClinicalMedicine – Lancet journals
- European Urology
- European Urology Oncology
- Journal of the National Cancer Institute
- Journal of ImmunoTherapy for Cancer
- Lancet Regional Health – Lancet journals
- Nature Communications
- NPJ Digital Health

(Top 10% journals in the field)

- ASCO – Journal of Clinical Informatics
- ASCO – Journal of Global Oncology
- Asia-Pacific Journal of Clinical Oncology
- British Journal of Radiology
- British Journal of Cancer
- Cancer Immunology Research
- Cancer
- Cancer Letters
- Cancer Medicine
- Expert Opinion on Therapeutic Targets
- European Journal of Cancer
- International Journal of Cancer
- Molecular Cancer Research
- Therapeutic Advances in Medical Oncology
- International Journal of Radiation, Oncology, Biology and Physics (Red J)
- Radiotherapy & Oncology (Green J)
- Oral Oncology

Grant Review Panels

- Kuwait Federation to Advance Science (KFAS)
- Canadian Cancer Society
- Medical Research Council (MRC), UK

- Agence Nationale de la Recherche, FR
- National Medical Research Council Singapore (NMRC)
- NCCS Research Fund
- Duke-NUS Academic Medicine Centre Grant Review Committee
- Duke-NUS Oncology Academic Clinical Program Grant Review Committee

Conference Scientific Committees

2025, Jun	Chair, Radiation Oncology Education Track, ESMO Asia Congress 2025, Singapore
2025, May	Chair, Radiation Oncology Track, International Federation of Head and Neck Oncologic Societies World Congress 2026
2025, Jan	Member, International Conference of Head and Neck Oncology (ICHNO) 2026 – Translational Science Track
2025, Jan	Member, ESMO Congress 2026 Scientific Committee – Head and Neck Cancer Track
2024, Dec	Co-Chair, Radiation Oncology Education Track, ESMO Asia Congress 2024, Singapore
2024, Nov	Member, Advisory Committee of the International Conference on Advances in Radiation Oncology (ICARO-4)
2023, Dec	Co-Chair, Radiation Oncology Education Track, ESMO Asia Congress 2023, Singapore
2023, Aug	Chair, 2024 ASCO Breakthrough Meeting Committee, Yokohama
2023, Jul	Interdisciplinary Scientific Advisory Group Member, Joint FARO-ESTRO Congress 2024
2022, Dec	Co-Chair, Radiation Oncology Education Track, ESMO Asia Congress 2022, Singapore
2022, Sep	Teaching Faculty, ESMO Head and Neck Cancer Preceptorship 2022, Singapore
2022, Aug	Chair-elect, 2023 ASCO Breakthrough Meeting Committee, Yokohama
2022, Jul	Chair, Head and Neck Cancer Track, Singapore Society of Oncology Annual Scientific Meeting 2022, Singapore
2022, Jul	Member, Program Committee, International Congress of Radiation Research (ICRR) 2023, Montreal
2021, Nov	SSO Member Representative, Pan-Asian Guidelines Adaptation (PAGA) of the ESMO Guidelines for Prostate Cancer
2021, Sep	Teaching Faculty, ESMO Head and Neck Cancer Preceptorship 2021, Virtual
2021, Sep	Co-Chair, Oncology Academic Programme, SingHealth-Duke NUS Annual Scientific Congress 2021, Singapore
2021, Apr	Chairperson and Organising Committee, NCCS Artificial Intelligence and Data Science Seminar
2021, Mar	Teaching Faculty, ESMO Advanced Course on clinical questions in Prostate Cancer, Singapore
2021, Feb	Chair, Scientific Committee, Singapore Society of Oncology Annual Scientific Meeting 2021, Virtual
2020, Nov	Co-Chair, AI and Healthcare Plenary Session, Clinical Oncology Society of Australia Annual Scientific Meeting-ASCO Breakthrough Summit 2020, Virtual
2020, Sep	Co-Chair, Radiation Oncology Education Track, ESMO Asia Congress 2020, Singapore
2019, Nov	Co-Chair, Radiation Oncology Education Track, ESMO Asia Congress 2019, Singapore
2019, Nov	Teaching Faculty, 1 st SingHealth Uro-oncology Preceptorship, Singapore

2019, Sep	Co-Chair, Oncology Academic Programme, SingHealth-Duke NUS Annual Scientific Congress 2020, Singapore
2019, Sep	Teaching Faculty, ESMO Advanced Course on clinical questions in Prostate Cancer, Singapore
2019, Sep	Member, Scientific Program Steering Committee, ESMO Asia Congress 2020, Head and Neck Cancer, Singapore
2019, Jun	Chair, NCCS-ICRU Commission Meeting 2019, Singapore
2019, Apr	Teaching Faculty, ESMO Head and Neck Cancers Preceptorship, HK
2018, Nov	Co-Chair, Radiation Oncology Planning workshop, ESMO Asia Congress 2018, Singapore
2018, Nov	Teaching Faculty, ESMO Genitourinary Cancers Preceptorship, Singapore
2018, Nov	Chair, Clinical Indications in Head and Neck Tumors Track, 1st International Proton Therapy Educational Programme – Jointly held by PTCOG and Apollo Proton Cancer Centre, Chennai
2018, Sep	Member, Scientific Program Steering Committee, ESMO Asia Congress 2019, Head and Neck Cancer, Singapore
2018, Sep	Teaching Faculty, ESMO Advanced Course on clinical questions in Prostate Cancer, Singapore
2018, Sep	Teaching Faculty, ESMO Preceptorship on Metastatic Bladder and Kidney Cancer, Singapore
2017, Dec	Teaching Faculty, ESTRO-SEAROG Head and Neck Teaching Course, Singapore
2017, Nov	Co-Chair, Radiation Oncology Planning workshop, ESMO Asia Congress 2017, Singapore
2017, Nov	Teaching Faculty, ESMO Asia 2017 Genitourinary Cancers Preceptorship, Singapore
2017, Oct	Faculty Member, ASCO-ASTRO-CSCO International Clinical Trials Workshop, Luoyang
2016, Dec	Chair, Neuro-oncology Track, ESMO Asia Congress 2016, Singapore
2015, May	Chair, Scientific Committee, Inaugural Radiology Asia in conjunction with 24th Singapore Radiological Society Annual Meeting, Singapore
2014, Dec	Member, Scientific Committee, 1 st Asia-Pacific Prostate Cancer Advances, Singapore
2014, Jan	Chair, Radiation Oncology Track, 2 nd International Symposium of Training Plan for Oncology Professionals, 7-University Joint Project, Osaka

Invited Speaker / Lectureship (>300 talks; 30 Keynote lectures)

2025, Jun	2025 China Anti-Cancer Association Symposium on Nasopharyngeal Carcinoma Keynote Lecture, Guangzhou; <i>Presentation title: Radiotherapy for Nasopharyngeal Carcinoma – Is Proton Beam Therapy Better?</i>
2025, Jun	ASCO Annual Meeting 2025, Chicago; <i>Presentation title: Novel Approaches to the Treatment of Locally Advanced Nasopharyngeal Carcinoma</i> *Chair and Presenter
2025, May	Novogene Symposium 2025, Singapore; <i>Presentation title: Defining Future Care of Nasopharyngeal Carcinoma through Precision Trials and Omics</i>
2025, Apr	EORTC Head Neck Cancer Meeting Keynote Lecture, Lyon; <i>Presentation title: Radiotherapy in the Treatment of Locoregionally-Advanced Nasopharyngeal Carcinoma – Target Delineation and Proton Beam Therapy (A Confluence of Art and Science)</i>
2025, Apr	EUSICA-INSICA-BRAIN-REFCOR Meeting 2025 Keynote Lecture, Paris; <i>Presentation title: Precise Stratification and Management of Nasopharyngeal Carcinoma in 2025 – From Bedside to the Bench</i>

2025, Mar	National Tsing Hua University Academic Visit, Taiwan; <i>Presentation title: The Precision Radiotherapeutics Oncology Programme – National Cancer Centre Singapore</i>
2025, Mar	International Workshop on Diagnosis and Treatment of Nasopharyngeal Carcinoma, Guangzhou; <i>Presentation title: The Importance of the AJCC/UICC Expert Panel for Development of the TNM-9 Staging System for Nasopharyngeal Carcinoma</i>
2025, Mar	Chong Qing Medical Technology Association Meeting, Chong Qing; <i>Presentation title: Radiotherapy for Nasopharyngeal Carcinoma – Merging Science with Art</i>
2025, Jan	NCRI International Oncology Summit Keynote Lecture, Kolkata; <i>Presentation title: Conventional to Ultrahypofractionation – the Journey of Prostate Radiation Therapy</i>
2024, Dec	BeiGene symposium: Putting Science into Practice – Immuno-oncology in the Management of Nasopharyngeal Carcinoma, Singapore; <i>Presentation title: Importance of Multi-disciplinary Team Management in Nasopharyngeal Cancer</i>
2024, Dec	ESMO Asia Congress 2024, Singapore (x2 talks): <i>Presentation titles:</i> <i>Accuracy of Plasma Epstein-Barr virus (EBV) DNA for Disease Surveillance in Endemic Nasopharyngeal Carcinoma (NPC): Analysis of a Real-world Database (RWD)</i> <i>Lymphocyte-sparing Radiotherapy in the era of Immunotherapy</i>
2024, Nov	8 th Sun Yat-Sen University Cancer Centre International Head Neck Symposium, Guangzhou; <i>Presentation title – Delineation of Radiotherapy Target Volume of Nasopharyngeal Carcinoma: Contemporary Considerations and Guideline Development Process</i>
2024, Nov	Joint Satellite Symposium Seminar on Development of the AJCC and UICC TNM Staging Classification Ninth Version for Nasopharyngeal Carcinoma, Xi'an; <i>Presentation title: Developmental Process of TNM-9 for Staging of Nasopharyngeal Carcinoma</i>
2024, Nov	Frontiers in Cancer Science 2024; <i>Presentation title: Multi-dimensional Approach to Investigate Cancer Radioresistance – A Marriage of Systems Biology and Reductionistic Approaches</i>
2024, Oct	35 th Annual Scientific Conference of Malaysia Oncology Society (x2 talks): <i>Presentation titles:</i> <i>Coaching Trainees in the era of Abundance of Online Resources</i> <i>Reinventing the Wheel for Radiotherapy in Nasopharyngeal Carcinoma</i>
2024, Sep	ESMO Congress 2024, Barcelona; <i>Presentation title: Individualising Induction and Concurrent Systemic Therapy in Locoregionally-advanced NPC – Transitioning Evidence to Real-world Practice</i>
2024, Aug	ESTRO meets Asia 2024, Kuala Lumpur; <i>Presentation title: Toxicity Profile of Radiation Therapy in combination with Immunotherapy</i>
2024, Jul	2024 UROFAIR, Singapore; <i>Presentation title: Asian Prostate Cancer Genomics – Insights into Differential Biology and Treatment Responses</i>
2024, Jul	Joint NCCS and Duke-NUS Annual Scientific Retreat, Singapore; <i>Presentation title: Integrating Genomics and Precision Clinical Trials in NPC – The Singapore NPC Large Collaborative Programme</i>
2024, Jul	Visiting Professorship Keynote Lecture: Wuhan University, Wuhan; <i>Presentation title: The Singapore NPC Large Collaborative Programme</i>

2024, Jun	2024 China Anti-Cancer Association Symposium on Nasopharyngeal Carcinoma, Guangzhou; <i>Presentation title: Optimising Combinations for Radiotherapy and Systemic Chemotherapy in NPC</i>
2024, Jun	Gordon Research Conference Nasopharyngeal Carcinoma 2024 – Nasopharyngeal Carcinoma and Beyond: Elucidating Pathogenic Mechanisms and Developing Novel Therapeutics, Les Diablerets; <i>Presentation title: Translating Genomics to Personalised Therapeutic Strategies in NPC</i>
2024, May	Gustave Roussy Institute of Oncology Department of Radiation Oncology Journal Club, Virtual; <i>Presentation title: The Singapore NPC Large Collaborative Programme – Staying Relevant in a Competitive World</i>
2024, Apr	Varian-FARO 6 th education webinar; <i>Presentation title: Challenges with Hypofractionation Utilisation in the Asia Pacific Region: Insights from a Thought Leadership Council</i>
2024, Mar	9th International Congress on Innovative Approaches in Head and Neck Oncology Keynote Lecture, Barcelona; <i>Presentation title: Circulating Tumour DNA for Disease Management and Follow-up of Head and Neck Cancers</i>
2024, Mar	BeiGene Head and Neck Cancer Symposium, Guangzhou; <i>Presentation title: Advances in Head and Neck Radiotherapy</i>
2024, Mar	12 th NPC Research Day Universiti Malaya, Kuala Lumpur; <i>Presentation title: Future of Personalised Therapies in NPC</i>
2024, Mar	2024 Multidisciplinary Head and Neck Cancer Symposium, Phoenix; <i>Presentation title: Molecular Profiling of Treatment Responses and Personalised Therapy for NPC</i>
2023, Nov	ESMO Asia Congress 2023, Singapore; <i>Presentation title: Challenges to Overcoming Radioresistance in Head and Neck Cancers</i>
2023, Nov	10 th Croatia Prostate Tumori Congress, Zagreb; <i>Presentation title: Takes 2 to Tango – Systemic therapy combinations and Genomics for Precision Medicine in Prostate Cancer</i>
2023, Nov	Joint Brescia Meetings in Radiation Oncology (2023 Edition) and AIRO LOMBARDIA – 2nd Scientific Meeting 2023, Brescia; <i>Presentation title: Induction Chemotherapy and Adjuvant Treatment in Locally Advabnced Nasopharyngeal Cancer</i>
2023, Oct	Duke-NUS Health Data Science Symposium 2023, Singapore; <i>Presentation title: High Quality Oncology Data to Inform on Clinical Trials Design</i>
2023, Oct	SingHealth-Duke NUS Global Health Institute Artificial Intelligence Webinar Series, Singapore; <i>Presentation title: Big Data and AI in Head Neck Cancer Radiotherapy Planning</i>
2023, Oct	ESMO Congress 2023, Madrid (x2 talks); <i>Presentation titles:</i> <i>Immunotherapy for Head and Neck Cancer – Perspectives</i> <i>Clinical application of plasma EBV DNA in individualising treatment of locoregionally-advanced nasopharyngeal carcinoma – Recent advances and real-world applications</i>
2023, Sep	Baltic Congress of Surgeons and Oncologists 2023, Tallinn; <i>Presentation title: Precision Oncology of Today and Tomorrow – Liquid Biopsies in Cancer</i>
2023, Aug	SingHealth ENT Head and Neck Instructional Course 2023 – Improving Outcomes in Head and Neck Surgery Virtual Symposium, Singapore; <i>Presentation title: Big Data and AI in Head Neck Cancer Radiotherapy Planning</i>

2023, Aug	Asian-Oceania Congress of Neuroradiology 2023, Singapore; <i>Presentation title: Challenges of instituting an NPC screening program</i>
2023, Jul	2nd Guangzhou Nasopharyngeal Carcinoma Clinical Trials Meeting, Guangzhou; <i>Presentation title: Systemic Therapy in Locally Advanced Nasopharyngeal Carcinoma: Past, Present, and Future</i>
2023, Jul	UROFAIR Plenary 2023, Singapore; <i>Presentation title: Role of Radiotherapy in the management of Metastatic Prostate Cancers</i>
2023, Jul	SSO Annual Scientific Meeting 2023, Singapore; <i>Presentation title: Role of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma</i>
2023, Jul	1 st Malaysia Oncology-Haematology Summit 2023, Kuala Lumpur; <i>Presentation title: From Diagnosis to Decision-Making: A Comprehensive Approach to mHSPC</i>
2023, Jun	2023 Asia Pacific Prostate Cancer Next Generation Imaging Preceptorship Program, Shanghai (x 3 talks); <i>Presentation titles:</i> <i>PSMA imaging – Disruptive Technology to Reshape Risk Stratification and Treatment of Localised/Recurrent Prostate Cancers</i> <i>How can we leverage PSA as a useful biomarker to select and optimize treatment?</i> <i>Multidisciplinary Team Management of Genitourinary Cancers</i>
2023, Jun	Pre-ASCO China Summit 2023; <i>Presentation title: Next-generation Advances in Cancer – A Prelude to ASCO Breakthrough 2023</i>
2023, May	ASCO Breakthrough 2023: Next Big Thing in Cancer, Japan; <i>Presentation title: Next-generation Multiomics and Precision Oncology with AI</i>
2023, Apr	Varian Oncology Summit, HK; <i>Presentation title: Multidisciplinary Team in the Management of Head and Neck Cancers</i>
2023, Apr	CNAO Research Seminar, Pavia; <i>Presentation title: Clinical trials and translational research in nasopharyngeal carcinoma</i>
2023, Mar	2 nd Journal of the National Cancer Centre Summit, Beijing; <i>Presentation title: How to design a good research study and skills to writing a good research paper</i>
2023, Mar	Thailand Society of Radiation Oncology Annual Meeting 2023 (x2 talks); <i>Presentation titles:</i> <i>Current paradigm in nasopharyngeal carcinoma treatment</i> <i>Challenging points and future direction in radiotherapy for head and neck cancers</i>
2023, Feb	UCSF Oncology Grand Rounds, San Francisco; <i>Presentation title: Nasopharyngeal Carcinoma – Integration into Practice and Future Research</i>
2023, Jan	Varian Asia-Pacific Japan India symposium, Bangkok; <i>Presentation title: Challenges in multi-disciplinary cancer care and call to action</i>
2023, Jan	eChinaHealth – Next Big Thing in Cancer Cancer, pre-JP Morgan Healthcare Conference webinar; <i>Presentation title: Next-generation multiomics technology and precision oncology with AI</i>
2022, Dec	Guangzhou Nasopharyngeal Carcinoma Clinical Trials Meeting, Guangzhou; <i>Presentation title: EBV DNA and genomics to design precision medicine clinical trials in nasopharyngeal carcinoma</i>

2022, Dec	CNAO Head Neck Education Webinar – Think HADROM; <i>Presentation title – Proton beam therapy in nasopharyngeal carcinoma</i>
2022, Dec	6 th Sun Yat-Sen University Cancer Centre International Head Neck Symposium; <i>Presentation title – Proton beam therapy in nasopharyngeal carcinoma – Current evidence and future directions in 2022</i>
2022, Dec	ESMO Asia Congress 2022, Singapore (x2 talks); <i>Presentation titles:</i> <i>Potential benefits and limitations of immunotherapy in localised head and neck cancer – Radiation oncologist perspectives;</i> <i>Hypofractionation in radiotherapy – State of the art in prostate cancer in 2022</i>
2022, Nov	SingHealth Head and Neck Teaching Round, Virtual; <i>Presentation title: What’s New in the Treatment of Nasopharyngeal Carcinoma in 2022</i>
2022, Nov	NCCS-Duke-NUS Joint Research-in-progress Meeting; <i>Presentation title: RIBBON trial and the Singapore NPC Large Collaborative Grant – A glimpse into translational NPC research at NCCS</i>
2022, Nov	33 rd Annual Scientific Meeting Malaysian Oncology Society, Kuala Lumpur; <i>Presentation title: Reirradiation in head and neck Cancer – How “safe” is safe?</i>
2022, Oct	ASTRO Annual Meeting, San Antonio; <i>Presentation title: International Efforts in Radiation Oncology AI: Lessons Learned From Around the Globe</i>
2022, Oct	CACA-UICC International Session on Fostering Collaboration for Integrated Cancer Control in Belt and Road Countries, Virtual; <i>Presentation title: Building collaborations in the region from the clinician’s perspective: the ASCO’s Leadership Development Program Asia-Pacific (LDP-AP)</i>
2022, Sep	ESMO Head and Neck Cancer Preceptorship, Virtual; <i>Presentation title: Management of localised nasopharyngeal carcinoma</i>
2022, Sep	Merck Sharp & Dohme (MSD) Head and Neck Cancer Scientific Symposium 2022, Virtual; <i>Presentation title: Management of locally advanced head and neck cancer: Current practice and gaps</i>
2022, Sep	Houston Methodist Oncology Grand Rounds, Houston; <i>Presentation title: Precision Oncology in Nasopharyngeal Carcinoma – How can the rest of the world learn from an Asian disease?</i>
2022, Aug	Janssen PACman series – Multidisciplinary Team Management in Prostate Cancer, Malaysia; <i>Presentation title: Heterogeneity in the Treatment of Advanced Castrate-Sensitive Prostate Cancer</i>
2022, Aug	SPOT contouring course series 2022 organised jointly by Radoncoasia and National University Hospital Singapore, Singapore; <i>Presentation title: Target Delineation in Nasopharyngeal Carcinoma in the era of Induction Chemotherapy</i>
2022, Jul	World Head and Neck Cancer Day, Virtual; <i>Presentation title: Treatment of Nasopharyngeal Carcinoma</i>
2022, Jun	Current management and future challenges in Salivary Glands Cancer, Pavia; <i>Presentation title: Current management of high-grade salivary gland cancer from nasopharynx, palate and paranasal sinuses: the radiation oncologist’s point of view</i>
2022, May	NHMed Symposium 2022, Singapore; <i>Presentation title: Research in Healthcare</i>

2022, May	Kyoto National Cancer Centre Urology Symposium, Kyoto; <i>Presentation title: The Plato's Tripartite – Management of Advanced Prostate Cancer in 2022: Next-generation Imaging, Radiotherapy, and Next-generations Agents</i>
2022, May	Gordon Research Conference Nasopharyngeal Carcinoma 2022 – Nasopharyngeal Carcinoma and Beyond: Lesson and Learnings from Nasopharyngeal Carcinoma and other Virus-associated Cancers, Barcelona; <i>Presentation title: Matching Genotypes to Phenotypes to Treatment – What do we know in 2022?</i>
2022, Apr	Singapore Urological Association CME Under the Stars – Decoding Prostate Cancer, Singapore; <i>Presentation title: Genetic Testing to Personalize Prostate Cancer Treatment in Organ Confined Disease</i>
2022, Apr	NCCS Research Meeting, Singapore; <i>Presentation title: Precision Radiation Oncology Programme and Data and Computational Science Core</i>
2022, Mar	NCCS Division of Radiation Oncology Head and Neck Peer Review Learning Rounds, Singapore; <i>Presentation title: QUAD-CHECK: A case-series of exceptional responders to pembrolizumab and moderate-hypofractionated radiotherapy in anaplastic thyroid cancers</i>
2022, Feb	13th Federation of Asian Radiation Oncology (FARO) Webinar, Novel agents & Techniques for Prostate Cancer, Virtual; <i>Presentation title: Use of Novel Agents with Prostate Radiotherapy</i>
2022, Jan	SingHealth AI EXCO Committee Meeting, Singapore; <i>Presentation title: Data Science Computational Core at the National Cancer Centre Singapore</i>
2022, Jan	Astellia-sponsored Education Symposium – Changi General Hospital Urology Rounds, Virtual; <i>Presentation title: Update of evidence on management of metastatic castrate-sensitive prostate cancer and non-metastatic castrate-resistant prostate cancer</i>
2021, Dec	ESMO Advanced Course on clinical questions in Prostate Cancer, Virtual (x2 talks); <i>Presentation titles: Advances of Radiotherapy Modalities in the Treatment of Localised Prostate Cancer; Oligometastatic Prostate Cancer</i>
2021, Dec	Cancer Project ECHO, University of Malaya, KL; <i>Presentation title: Management of locoregional recurrent nasopharyngeal carcinoma</i>
2021, Nov	Duke-NUS-SingHealth AMC Press Release, Singapore (featured in Channel Newsasia, Straits Times, Channel 8 News); <i>Presentation title: PASPORT – Parallel Amplified Saliva Point-of-care Test for COVID-19</i>
2021, Nov	8 th Annual Prostate Cancer Symposium by the Croatian Academy of Sciences and Arts, Zagreb; <i>Presentation title: Role of radiotherapy in the treatment of prostate cancer – Recent advances in modalities</i>
2021, Nov	3 rd Experts on advancing the Management of Prostate cancer through knowledge and Experience (EMPOWER) meeting, Virtual; <i>Presentation title: Risk stratification by volume of disease with Next-generation imaging in mCSPC</i>
2021, Nov	9 th Joint Scientific Meeting of RCR and HKCR and 29 th Annual Scientific Meeting of HKCR, HK; <i>Presentation title: Radiotherapy – Teaching an Old Dog New Tricks to Overcome Primary Resistance to Immunotherapy</i>
2021, Nov	Nasopharyngeal Cancer Screening Conference 2021 – Recent Advances in Screening and Early Detection of Nasopharyngeal Carcinoma: Is it Time to Act?, HK; <i>Presentation title: Experience with NPC screening in Singapore</i>

2021, Oct	SeCURE – The 28th Postgraduate Course of St. Luke's Institute of Urology Keynote Lecture; Presentation title: Next-generation imaging in advanced prostate cancer
2021, Oct	Bayer Singapore Darolutamide Launch Symposium, Singapore; <i>Presentation title: Non-metastatic castrate-resistant prostate cancer – A Radiation Oncologist's perspective</i>
2021, Oct	Special Ministerial Conference for ASEAN Digital Public Health, Singapore; Moderator for Ministerial and Global Expert Panel: Collaboration in Public Health
2021, Sep	ESMO Head and Neck Cancer Preceptorship, Virtual; <i>Presentation title: Management of localised nasopharyngeal carcinoma</i>
2021, Sep	ESMO Congress 2021, Paris; Presentation title: Bedside to Bench – Locoregional therapies in the management of acquired resistance to immunotherapy
2021, Sep	SingHealth-Duke NUS Scientific Congress, Singapore; <i>Presentation title: Debate (Proposition) – The house believes that future innovation technologies will render surgeons obsolete in the treatment of cancer</i>
2021, Sep	Philippines Radiation Oncology Society Annual Scientific Meeting, Manila; <i>Presentation title: Immunooncology implications in the management of head and neck cancers and nasopharyngeal carcinoma</i>
2021, Aug	Janssen PACman series – Multidisciplinary Team Management in Prostate Cancer, Malaysia; <i>Presentation title: Updated TITAN final analysis on the role of apalutamide in metastatic castrate-sensitive prostate cancer</i>
2021, Aug	54 th Malaysia-Singapore Congress of Medicine in conjunction with the College of Surgeons, Academy of Medicine of Malaysia Annual Scientific Congress, Malaysia; <i>Presentation title: Innovation and Patient Navigation Tools to Improve Cancer Care</i>
2021, Aug	ASEAN Head and Neck Network, Virtual; <i>Presentation title: Non-surgical treatment of head and neck cancer with unknown primary</i>
2021, Aug	2021 China International Exchange and Promotive Association for Medical and Health Care – Nasopharyngeal Cancer Branch Inaugural Conference Keynote Lecture, Nanchang; Presentation title: Clinical application & mechanisms of radiation therapy & immune checkpoint blockade
2021, Aug	Urological Association of Asia Congress, Virtual; <i>Presentation title: Is there still a role for adjuvant radiotherapy post-prostatectomy?</i>
2021, Jul	Pan-Apollo Molecular Multidisciplinary Tumour Board, Chennai; <i>Presentation title: QUAD-CHECK – A Case Series of Exceptional Responders to Pembrolizumab and Moderate-hypofractionated Radiotherapy in Anaplastic Thyroid Cancer</i>
2021, Jul	Janssen PACman series – Multidisciplinary Team Management in Prostate Cancer, Malaysia; <i>Presentation title: Metastatic Castrate Sensitive Prostate Cancer with Extreme Response to Apalutamide</i>
2021, Jun	Janssen Joint Malaysia-Singapore Education Seminar, Virtual; <i>Presentation title: Navigating the Treatment of Patients with Metastatic Castration Sensitive Prostate Cancer</i>
2021, Jun	NCRIS Research-in-progress meeting, Singapore; <i>Presentation title: Translational Proton Therapy Research – Leveraging on the “Big Machine” to target radioresistance</i>
2021, Jun	UROFAIR Oncology – Ferring sponsored symposium 2021, Virtual; <i>Presentation title: Contemporary Androgen Deprivation Therapy in Elderly Patients with Advanced Prostate Cancer: Issues and Concerns</i>

2021, Jun	SingHealth Head and Neck Teaching Round, Virtual; <i>Presentation title: What's New in the Treatment of Nasopharyngeal Carcinoma</i>
2021, Jun	UROFAIR Nursing Masterclass 2021, Virtual; <i>Presentation title: Staging and Imaging of Advanced Prostate Cancer</i>
2021, Jun	7th Asian Society of Head and Neck Oncology Meeting, Malaysia (x2 talks); <i>Presentation titles:</i> <i>Chemoradiation in Salivary Gland Malignancies</i> <i>Grand Debate: Early Glottic Cancer – Proponent for Radiotherapy over Surgery</i>
2021, May	Janssen Asia-Pacific Seminar, Virtual; <i>Presentation title: Contemporary Imaging in Prostate Cancer: Gimmicks or Game-changers</i>
2021, Apr	Janssen Asia-Pacific Advisory Board 2021, Virtual; <i>Presentation title: Current Views and New Developments in Metastatic Hormone-Sensitive Prostate Cancer</i>
2021, Apr	Immuno-Oncology Hong Kong 2021, Hong Kong; <i>Presentation title: Immuno-Oncology and Radiotherapy for Head and Neck Cancer</i>
2021, Apr	NCCS Artificial Intelligence and Data Science Inaugural Seminar; <i>Presentation title: Making sense of randomness, missingness, and bias in real-world datasets – Nasopharyngeal carcinoma as a use case</i>
2021, Mar	ESMO Advanced Course on clinical questions in Prostate Cancer, Virtual (x2 talks); <i>Presentation titles:</i> <i>Advances of Radiotherapy Modalities in the Treatment of Localised Prostate Cancer;</i> <i>Oligometastatic Prostate Cancer</i>
2021, Mar	Janssen-sponsored Seminar on Management of Metastatic Hormone-sensitive Prostate Cancer, Virtual; <i>Presentation title: Oligometastatic hormone-sensitive prostate cancer with dramatic response to first-line novel hormonal therapy</i>
2021, Mar	TROG Annual Scientific Meeting 2021 Plenary, Virtual; <i>Presentation title: Clinical Considerations for Proton Beam Therapy and Future Directions</i>
2021, Feb	Duke-NUS Student Interest Group Seminar Series; <i>Presentation title: Introduction to Proton Beam Therapy in Radiation Oncology</i>
2021, Feb	JSMO Annual Meeting 2021, ASCO-JSMO Breakthrough Meeting Insights, Kyoto; <i>Presentation title: AI in Clinical Practice</i>
2020, Dec	Multidisciplinary Approach in Treating Cancers of the Head and Neck (MATCH) Programme, Virtual; <i>Presentation title: Management of locally advanced oral tongue cancer in a young patient</i>
2020, Nov	ESTRO 2020 Plenary, Virtual; <i>Presentation title: Updates in Advances in Non-metastatic Nasopharyngeal Carcinoma in 2020</i>
2020, Nov	ESMO Asia Congress 2020, Singapore (x2 talks); <i>Presentation titles:</i> <i>Contemporary concepts in the radiotherapy treatment of oropharyngeal squamous cell carcinoma;</i> <i>Management of muscle-invasive bladder cancer: how to optimise surgery, radiotherapy and chemotherapy</i>
2020, Nov	Clinical Oncology Society of Australia Annual Scientific Meeting-ASCO Breakthrough Summit 2020 Plenary Session, Virtual; <i>Presentation title: AI in practice</i>

2020, Nov	12 th Frontiers in Cancer Science, Singapore; <i>Presentation title: Evolution of Clinical Trials in Nasopharyngeal Carcinoma: Conceptualising the Next-generation of Phenotype-directed Trials</i>
2020, Oct	ASTRO Annual Meeting, Virtual; <i>Presentation title: EBV DNA and its utility for precision treatment strategies in nasopharyngeal carcinoma</i>
2020, Oct	ImmunoSCAPE virtual webinar, Virtual; <i>Presentation title: High dimensional profiling of the immune system informs on synergy between radiotherapy and immunotherapy</i>
2020, Oct	Asia-Pacific Advanced Prostate Cancer Consensus Symposium, Singapore; <i>Presentation title: Management of the primary tumour in the metastatic setting</i>
2020, Sep	The Radiation Lecture Exchange Series – The RadOnc Virtual Visiting Professor Network, Colorado; <i>Presentation title: Evolution of Chemoradiotherapy Trials in Nasopharyngeal Carcinoma – “A Hobbit’s Journey: There and Back Again”</i>
2020, Jul	UROFAIR Masterclass 2020, Singapore; <i>Presentation title: Case study presentation on management of oligometastatic node-positive with combinatorial novel hormonal therapy and local treatment</i>
2020, Jun	4th South East Asia Prostate Cancer Core Faculty Meeting (PACER), Virtual; <i>Presentation title: Management of non-metastatic castrate-resistant prostate cancer – when to treat and consequences of not treating</i>
2020, Jun	Russian and Kazakhstan Medical Society Together against Cancer Foundation – Cancer and COVID-19 webinar, Virtual; <i>Presentation title: Cancer Care and COVID-19 – Ensuring Delivery of Care in Singapore and China</i>
2020, Apr	Global Consortium for Radiotherapy 1 st Taskforce Meeting, Virtual; <i>Presentation title: COVID-19 and Patients with Cancer – the Wuhan experience</i>
2020, Mar	Janssen-sponsored Seminar on Management of Metastatic Hormone-sensitive Prostate Cancer, Virtual; <i>Presentation title: Embracing a diversity of options in a rapidly evolving therapeutic landscape</i>
2020, Feb	Japan Team Oncology Program – 8 th ECHO Clinic, Virtual; <i>Presentation title: Induction Chemotherapy and Managing Locoregional Recurrences in Nasopharyngeal Carcinoma</i>
2020, Jan	Sun Yat-Sen University Cancer Centre Nasopharyngeal Carcinoma Clinical Trials Symposium, Guangzhou; <i>Presentation title: Future of phase II/III clinical trials in Nasopharyngeal carcinoma</i>
2019, Dec	3 rd Sun Yat-Sen University Cancer Centre International Head and Neck Cancer Symposium, Guangzhou; <i>Presentation title: Translational Research in Proton Beam Therapy – The NCCS strategy</i>
2019, Nov	ESMO Asia Congress 2019, Singapore (x2 talks); <i>Presentation titles:</i> <i>EBV DNA – the “hydra” of liquid biopsy in nasopharyngeal carcinoma (Proffered paper discussant);</i> <i>Management of paranasal sinus cancers</i>
2019, Nov	Janssen Education Seminar on Advanced Prostate Cancer, Singapore (x2 talks); <i>Presentation titles:</i> <i>Role of apalutamide in non-metastatic castrate-resistant prostate cancer;</i> <i>Real-world experience with use of apalutamide in high-risk prostate cancer</i>
2019, Nov	1 st Nasopharyngeal Carcinoma Guangzhou Summit Forum, Guangzhou; <i>Presentation title: Novel phenotype characterisation of nasopharyngeal carcinoma & next-generation clinical trials</i>

2019, Nov	11th Dr. Gina Villanueva Panuncialman Memorial Lecture (Keynote), Manila; Presentation title: A tale of two "cities (Gleason's and Genomics) in evolution of prostate cancer
2019, Nov	University of Santo Tomas Hospital-Benavides Cancer Institute 13 th Annual Cancer Conference, Manila (x2 talks); <i>Presentation titles:</i> <i>The evidence for hypofractionation in prostate cancer;</i> <i>Role of radiotherapy in metastatic hormone-sensitive and castrate-resistant prostate cancer</i>
2019, Nov	1 st SingHealth Uro-Oncological Preceptorship, Singapore; <i>Presentation title: Radiotherapy in Muscle-Invasive Bladder Cancer</i>
2019, Oct	ASCO Breakthrough Meeting, Bangkok; <i>Presentation title: Artificial Intelligence and Clinical Implementation</i>
2019, Sep	NCCS Public Education Forum, Singapore; <i>Presentation title: Diagnosis and Management of Prostate Cancer in 2019</i>
2019, Sep	ASTRO Annual Meeting, Chicago; <i>Presentation title: Immunotherapy in EBV-related Cancers</i>
2019, Sep	ESMO Advanced Course on clinical questions in Prostate Cancer, Singapore (x2 talks); <i>Presentation titles:</i> <i>Advances of Radiotherapy Modalities in the Treatment of Localised Prostate Cancer;</i> <i>Oligometastatic Prostate Cancer</i>
2019, Aug	Korea National Cancer Centre Special Seminar, Seoul; <i>Presentation title: Precision Oncology in Head and Neck Cancers – Novel Trial Design and Translational Proton Beam Research</i>
2019, Aug	3 rd International BRCA Forum, Singapore; <i>Presentation title: Radiotherapy considerations in BRCA mutation carriers</i>
2019, Aug	6 th National Cancer Institute of Singapore Annual Research Meeting; <i>Presentation title: Hearing the journey – A Decade's journey as a Clinician-Scientist</i>
2019, Jul	Visiting Professorship Keynote Lecture: Wuhan Zhongnan University, Wuhan; Presentation title: Setting up a global-leading head and neck cancer research programme – Clinical trials to translational science
2019, Jul	Nasopharyngeal carcinoma special seminar, Kunming; <i>Presentation title: Clinical trials in head and neck cancers: Conventional designs to next-generation biomarker-directed trials</i>
2019, Jul	Best of ASCO 2019, Singapore; <i>Presentation title: Gemcitabine and cisplatin induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicenter, randomized controlled trial</i>
2019, Jun	Saint Bartholomew Oncology Centre Special Seminar 2019, London; <i>Presentation title: Embracing the Future of Precision in Head and Neck Cancers – Next-generation clinical trials and proton beam therapy</i>
2019, Jun	UK National Head and Neck Oncology Meeting 2019, York; <i>Presentation title: Management of Nasopharyngeal Carcinoma in 2019 – Conventions and my Personalised Approach</i>
2019, Jun	NCCS-ICRU Commission Mini-Scientific Symposium 2019, Singapore; <i>Presentation title: An overview of the precision radiation oncology programme – shooting for the stars</i>
2019, Jun	43 rd Japan Head and Neck Society Annual Meeting – International symposium session, Kanazawa; <i>Presentation title: Evolution of chemoradiotherapy trials in nasopharyngeal carcinoma: From history lessons to next-generation biomarker-driven trials</i>

- 2019, May AACR New Horizons in Cancer Research, Shenzhen; *Presentation title: Novel drug combination designs to improve therapeutic ratio of radiotherapy: Leveraging on artificial intelligence and phenotypic profiling*
- 2019, May Sun Yat-Sen University Cancer Centre Nasopharyngeal Carcinoma Trialist Collaborators Meeting, Guangzhou; *Presentation title: Circulating tumor DNA to personalize treatment in nasopharynx cancer – Time to look “ahead”?*
- 2019, Apr ESMO Head and Neck Cancers Preceptorship, Hong Kong, SAR; *Presentation title: Epidemiology, anatomy and work-up of head and neck squamous cell cancers*
- 2019, Apr UROFAIR Masterclass 2019, Singapore; *Presentation title: Role of radiotherapy in advanced hormone sensitive and castrate resistant prostate cancer*
- 2019, Jan **Manchester Cancer Research Centre Invited Lectureship 2019, Manchester; *Presentation title: Precision treatment in nasopharynx cancer – From Big Data and Big Machine to N = 1***
- 2019, Jan 34th ESTRO-CERRO Meeting 2019, Les Menuires; *Presentation title: High dimensional immune profiling following stereotactic body radiotherapy alone or in combination with immune check-point blockade*
- 2019, Jan **Varian China Oncology Symposium Keynote Lecture 2019, Wuhan; *Presentation title: High dimensional tumour and microenvironment profiling informs on radioresistance and synergy between radiotherapy and immunotherapy***
- 2018, Nov ESMO Asia Congress 2018, Singapore (x4 talks)
Presentation titles:
SABR-COMET – Do we need to catch them all? (Proffered Paper Discussant);
Oligometastatic Prostate Cancer: Radiation Oncologist Perspective;
Role of Radiotherapy in Castrate Resistant Prostate Cancer;
IMRT vs Proton Beam Therapy in Locally Advanced Nasopharynx Cancer
- 2018, Nov ESMO Genitourinary Cancers Preceptorship, Singapore (x3 talks)
Presentation titles:
Role of Radiotherapy in Prostate Cancers – Recent Advances;
Advanced Prostate Cancer – Node-positive Disease and Current Status in 2018;
House debate: Motion (For) – Radiotherapy and Long-term Hormonal Therapy is the Standard of Care in Men with Locally Advanced Prostate Cancer
- 2018, Nov 2nd Sun Yat-Sen University Cancer Centre International Head and Neck Cancer Symposium 2018, Guangzhou; *Presentation title: Target Contouring in Head and Neck Radiotherapy – A Time-honoured Tradition in the era of Big Data and Big Machine*
- 2018, Oct Astellas Prostate Cancer Advisory Board Meeting; *Presentation title: Management of Non-metastatic Castrate-resistant Prostate Cancer: Review of SPARTAN and PROSPER Trial Data*
- 2018, Oct ASTRO Annual Meeting, San Antonio; *Presentation title: A Biopsy-based Genomic Classifier Predicts Biochemical Failure and Metastasis after Definitive Radiation without Hormone Therapy in a Prospective Cohort of Intermediate-risk Prostate Cancer*
- 2018, Sep ESMO Advanced Course on clinical questions in Prostate Cancer, Singapore (x3 talks);
Presentation titles:
Recent Advances on Radiotherapy Modalities in the Treatment of Localised Prostate Cancer;
Role of Radiotherapy (including Adjuvant Radiotherapy for High Risk Disease): Current Advances and where we stand now?
Oligometastatic Prostate Cancer: Current Data and Controversies

- 2018, Sep ESMO Preceptorship on Metastatic Bladder and Kidney Cancer, Singapore; *Presentation title: Role of Radiotherapy in Metastatic Bladder and Renal Cancers.*
- 2018, Sep Sun Yat-Sen University Cancer Centre Overseas Faculty Visit, Guangzhou; *Presentation title: Development of a Precision Radiation Oncology Programme in Nasopharynx and Prostate Cancers*
- 2018, Aug NCCS Scientific Advisory Board Review 2018; *Presentation title: Head and neck and proton beam research in the Precision Radiation Oncology Programme*
- 2018, Aug 1st Southeast Asia Prostate Cancer Centre of Excellence (x3 talks); *Presentation titles: Multidisciplinary prostate cancer care in NCCS; Biomarker research and the precision therapeutics programme in prostate cancer; Management of non-metastatic castrate-resistant prostate cancer (Expert panel discussion)*
- 2018, Jul UROFAIR Masterclass 2018, Singapore; *Presentation title: Loco-regional therapy for locally advanced prostate cancer in 2018*
- 2018, Jul UROFAIR 2018, Singapore; *Presentation titles: Management of Oligometastatic Prostate Cancer in 2018: Cytoreductive and metastasis-directed radiotherapy is the “silver bullet” we are looking for!*
- 2018, Jul Best of ASCO 2018, Singapore; *Presentation title: A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)*
- 2018, May Ferring-Singapore Education Symposium, Singapore; *Presentation title: Precision medicine in prostate cancer – Targeting and genomics*
- 2018, May Global Academic Programme (GAP6) Meeting 2018, Karolinska Institute, Stockholm; *Presentation title: High-dimensional immune surveillance following stereotactic ablative radiotherapy and immunotherapy*
- 2018, May PRACTICAL Prostate Cancer Consortia Meeting, Karolinska Institute, Stockholm; *Presentation title: DISCLOSE study – DIScovery of biomarkers for CLinical respOnSE to radiotherapy*
- 2018, Apr **NCCS Press Release, Singapore (featured in Lianhe Zaobao, Wanbao, Mediacorp Radio, 883Jia, Singapore Health); *Presentation title: PRANCIS – A precise clinical tool to select nose cancer patients to a repeat course of radiotherapy for cure***
- 2018, Apr Sun Yat-Sen University Cancer Centre Genomics and Computational Biology Meeting 2018, Guangzhou; *Presentation title: Precision Medicine and Genomics in Nasopharynx Cancer*
- 2018, Mar **Varian Oncology Summit Keynote Lecture 2018, Kuala Lumpur; *Presentation title: Immune surveillance following stereotactic ablative radiotherapy in combination with immunotherapy***
- 2018, Jan 1st Sun Yat-Sen University Cancer Centre International Head and Neck Cancer Symposium 2018, Guangzhou; *Presentation title: Precision Radiotherapy in Head and Neck Cancer – A Marriage of Genomics, Radiomics, and Immunologics*
- 2018, Jan 33rd ESTRO-CERRO Meeting 2018, Les Menuires; *Presentation title: A Clinico-Radiomics Prognostic Model for Stratification of Radioresistant Nasopharynx Cancer to Curative Salvage Radiotherapy*
- 2018, Jan Chang-Gung Memorial University-National University Singapore Joint Symposium, Singapore; *Presentation title: Overview of the Translational-Clinical Research under the NCCS Proton Research Programme*

- 2017, Dec ESTRO-SEAROG Head and Neck Teaching Course, Singapore (x2 talks) *Presentation titles: Management of Nasopharynx Cancer in 2017; Case-based discussion of management of nasopharynx cancers*
- 2017, Nov ESMO Asia Congress 2017, Singapore (x3 talks) *Presentation titles: Combinatorial approaches in head and neck cancers – Radiotherapy perspectives; Radiotherapy planning in complex head and neck cancers; Radiotherapy planning in complex genitourinary cancers*
- 2017, Nov ESMO Asia Genitourinary Cancers Preceptorship, Singapore (x3 talks) *Presentation titles: Role of radiotherapy in the management of prostate cancers in 2017; Management of node-positive prostate cancer – change in treatment paradigm; House debate: Motion (For) – Radiotherapy and long-term hormonal therapy is the standard treatment in all men with locally advanced prostate cancer*
- 2017, Oct ASCO International Clinical Trials Workshop (ICTW), Luoyang (x4 talks); *Presentation titles: Practicalities of Ethics in Clinical Research; Setting up a Successful Clinical Trials Team; Quality of Life and Survivorship Research in Clinical Trials; Planning a PhD and Post-doctoral Fellowship degree*
- 2017, Sep ASTRO Annual Meeting, Boston; *Presentation title: Genomic, epigenomic, and clonal architecture of prostate cancer at recurrence following radiotherapy*
- 2017, Aug NCCS Public Education Forum, Singapore; *Presentation title: Diagnosis and Management of Prostate Cancer in 2017*
- 2017, Aug Varian Scientific Symposium, Ho Chi Min City, Vietnam; *Presentation title: Precision Radiotherapy in Prostate Cancer – Marriage of Physical and Biological Precision*
- 2017, Jun **Invited speaker (Top 3 proffered paper), 15th International Wolfsberg International Meeting 2017, Ermatingen; Presentation title: Genomic architecture of radioresistant prostate cancer**
- 2016, Dec ESMO Asia Congress 2016, Singapore (x 2 talks); *Presentation titles: Re-irradiation of recurrent non-metastatic T3-4 nasopharyngeal carcinoma; Adjuvant radiotherapy in high-risk urothelial and variant histology bladder cancers*
- 2016, Sep Philips Special Genomics Seminar, Boston; *Presentation title: Precision medicine in localised prostate cancer – The Canadian Prostate Cancer Gene Network experience*
- 2016, Sep ASTRO Annual Meeting, Boston; *Presentation title: Genomic architecture of prostate cancer at recurrence following radiotherapy*
- 2016, Sep **Radiation Medicine Program Special Seminar, Princess Margaret Cancer Centre, Toronto; Presentation title: Nasopharyngeal carcinoma: Personalising treatment – Past, Present, and Future**
- 2016, Jul Invited poster presenter, Gordon Research Conference Nasopharyngeal Carcinoma, Hong Kong, SAR
- 2016, Apr AACR Annual Meeting, New Orleans; *Presentation title: Prognostic significance of copy number alteration burden in unfavourable intermediate-risk prostate cancers harbouring intraductal carcinoma and cribriform architecture*

2015, Dec	ESMO Asia Congress 2015, Singapore; <i>Presentation title: Brain metastases: Is whole brain radiotherapy indicated for most patients?</i>
2015, Dec	Asian-American Medical Group 1 st International Symposium on Minimally Invasive Oncology, Singapore; <i>Presentation title: Precision radiation oncology: Where technology meets biology</i>
2014, Dec	1 st Asia-Pacific Prostate Cancer Advances, Singapore; <i>Presentation title: Radiotherapy dose escalation studies in prostate cancer</i>
2014, Oct	ASTRO Annual Meeting, San Francisco; <i>Presentation title: Plasma EBV DNA as a predictive biomarker in patients with endemic nasopharyngeal carcinoma treated with induction chemotherapy and concurrent chemo-radiotherapy</i>
2014, Sep	Invited Country Representative Expert, IAEA Technical Meeting – Genetic characterisation and radiotherapy response of nasopharyngeal carcinoma, Vienna; <i>Presentation title: Chemotherapy in the treatment of nasopharyngeal carcinoma – Where are we in 2014?</i>
2014, Mar	Annual meeting of Philippines Radiation Oncology Society Keynote Lecture, Manila; <i>Presentation title: Radiobiology of SRS and SBRT – Should we or should we not believe the LQ?</i>
2014, Feb	1 st International Neuro-oncology workshop by Malaysia Oncology Society, Kuala Lumpur; <i>Presentation title: Cranio-spinal irradiation</i>
2014, Jan	2 nd International Symposium of Training Plan for Oncology Professionals, 7-University Joint Project, Osaka; <i>Presentation title: Predicting normal tissue radiosensitivity - where are we now and will we ever find the holy grail?</i>
2013, Mar	Joint International Symposium on EPR Dosimetry and Dating and the International Conference on Biological Dosimetry, Leiden; <i>Presentation title: DNA double-strand break repair and induction of apoptosis in relation to late normal tissue responses following radiotherapy for early breast cancer</i>
2012, Oct	ASTRO Annual Meeting, Boston; <i>Presentation title: DNA double-strand break repair and induction of apoptosis in relation to late normal tissue responses following radiotherapy for early breast cancer</i>
2012, Jul	5 th Systems Radiation Biology Workshop, Oxford; <i>Presentation title: Cellular radiation responses in skin tissues and blood lymphocytes in relation to late normal tissue effects of breast radiotherapy patients</i>
2008, Oct	8 th Asian Oceanian Society of Radiology Annual Meeting; <i>Presentation title: Comparison of the efficacy of PET/CT, conventional CT, and MRI in detecting intra-cranial extension of nasopharyngeal carcinoma</i>
2008, Sep	14 th Asean Association of Radiology Meeting, Hanoi; <i>Presentation title: Comparison of three modalities for skull base invasion in nasopharyngeal carcinoma</i>
2008, Jan	17 th Singapore Radiological Society Annual Scientific Meeting, Singapore; <i>Presentation title: Comparison of four different modalities for distant metastases staging in endemic nasopharyngeal carcinoma</i>

EDUCATION COMMITMENTS

Clinician-Scientists Supervisions

2023, Sep-Present	Overseas visiting post-doctoral scholar, Dr Xin Zhang, Chong Qing University Cancer Hospital, Chong Qing, China
-------------------	---

2022, Dec-2023, Oct	Overseas visiting post-doctoral scholar, Dr Jing Yu, Zhongnan Hospital of Wuhan University, Wuhan, China
2022, Feb-Dec	Overseas visiting post-doctoral scholar, Dr Jing Jing Miao, Sun Yat-Sen University Cancer Centre, Guangzhou, China
2021, Oct-2022, Aug	Mentor, ASCO Leadership Development Program
2021, Sep-Present	Lead Mentor, Clinician-Scientist Development Programme, Centre for Clinician Scientist Development+ (CCSD+), Duke-NUS Medical School
2021, Sep-Present	NMRC Transition Award mentor, Asst Prof Kae-Jack Tay, Department of Urology, Singapore General Hospital
2019, Sep-2020, Sep	Overseas visiting scholar, Dr Guang-Qiao Qin, The Affiliated Tumour Hospital of Guangxi Medical University, Guangxi, China
2019, Jul-2020, Jul	Overseas visiting scholar, Dr Luo Huang, Chong Qing University Cancer Hospital, Chong Qing, China
2018, Jun-2019, Aug	Overseas visiting scholar, Dr Zhongguo Liang, The Affiliated Tumour Hospital of Guangxi Medical University, Guangxi, China
2018, Sep-2019, Aug	Overseas visiting scholar, Dr Kai Yao, Sun Yat Sen University Cancer Centre, Guangzhou, China

Post-graduate Student Supervisions

2024, Jul-2025, Jan	ACE-in-grant programme, Transition Award mentee, Dr Frederick Koh
2023, Jul-Dec	ACE-in-grant programme, Transition Award mentee, Dr Stephanie P.L. Saw
2023, Jul-Present	Thesis Advisory Committee Member, Duke-NUS PhD candidate, Dr Choon Chiat Oh, Duke-NUS Medical School Clinical Sciences Programme
2022, Nov-2025, Feb	Thesis Advisory Committee Member, Duke-NUS PhD candidate, Dr Stephanie Saw, Duke-NUS Medical School Clinical Sciences Programme
2023, Apr-Jul	ACE-in-grant programme, Clinician Scientist Award mentee, Dr Jan Hau Lee
2023, Apr-Jul	ACE-in-grant programme, Transition Award mentee, Dr Tira J.Y. Tan
2020, Aug-2022, Jun	NUS PhD candidate, Mr Zhang Ziyang (joint PhD supervisor with Prof Zhang Yong, NUS Department of Biomedical Engineering and Dr Ian Cheong, Temasek Life Science Laboratories)
2020, Jun-2022, Jun	NUS PhD candidate, Mr Li Ming Chong (joint PhD supervisor with Prof Zhang Yong, NUS Department of Biomedical Engineering)
2018, Jul-Present	Duke-NUS PhD candidate, Dr Wen Long Nei (NMRC PhD research fellow), Duke-NUS Medical School Clinical Sciences Programme

Graduate Student Supervisions

2021, Jan-Mar	MSc student (Final year research elective), Ms Renu Chandra Segaran; <i>Project title: Radiobiological investigations on Proton Beam Therapy</i>
2020, May-Jun	MBBS student (4 th year elective), Ms Laura Ling Ying Tan; <i>Project title: Discovering Biomarkers of Radioresistance: A Clinical Paradox in Nasopharyngeal Carcinoma</i>
2018, Jan-Jun	BSc student (FYP year), Mr Joshua Chua; <i>Project title: Investigating the Role of Radiomics for Prognostication in Nasopharynx Cancer</i>

Board of examiners

2022, Dec	Examiner, PhD Qualifying Examination, Duke-NUS Medical School (Candidate: Dr Stephanie P.L. Saw); <i>Project title: Delineating the genomic landscape Of resected early stage EGFR-mutated non-small cell lung cancer (DECODE)</i>
2022, Nov	Chair and examiner, PhD Qualifying Examination, Duke-NUS Medical School (Candidate: Dr Tira J.Y. Tan); <i>Project title: Homologous Recombination Deficiency / BRCA-ness in Triple Negative Breast Cancers: Identifying Biomarkers of PARPi Responsiveness Beyond gBRCA Mutations</i>
2022, Nov	External examiner and assessor, University of Malaya Masters of Clinical Oncology Exit Examinations
2019, Jun	External examiner, University of Wollongong PhD defence (Candidate: Dr Bruce Graham Ashford); <i>Project title: The mutational landscape of metastatic cutaneous squamous cell carcinoma</i>
2018, Nov	External examiner, Sun Yat Sen University Cancer Centre PhD defence viva (Candidate: Mr Wei Liao); <i>Project title: Test of Circulating DNA as Biomarkers for the Diagnosis of Sepsis</i>
2018, Nov	External examiner, Sun Yat Sen University Cancer Centre PhD defence viva (Candidate: Mr Yu Kuai); <i>Project title: High Efficiency shRNA Design based on New microRNA Backbone</i>
2018, Nov	External examiner, Sun Yat Sen University Cancer Centre PhD defence viva (Candidate: Mr Jie-Rong Chen); <i>Project title: Genetic Studies of EBV-associated Malignancies</i>
2018, Nov	External examiner, Sun Yat Sen University Cancer Centre PhD defence viva (Candidate: Mr Shuwei Chen); <i>Project title: The Effects of Sam68 on Cisplatin Resistance in Oral Cavity Squamous Cell Carcinoma</i>

RESEARCH

Research Summary

I am a Clinician-Scientist with a joint appointment at the National Cancer Centre Singapore (NCCS) and the Duke-NUS Medical School. I am currently an Associate Professor (On Tenure) of Duke-NUS Medical School, Singapore; Visiting Professor of the Zhongnan Hospital of Wuhan University, China. I am also a Principal Investigator of the Precision Radiotherapeutics and Oncology Programme (PROP). Additionally, I am the Head of Department and Senior Consultant for the Department of Head and Neck and Thoracic Radiation Oncology, and Director of the Data and Computational Science Core at the NCCS.

Our work is supported by several National grants including: (1) the NMRC CSA (Investigator-category); (2) the National Research Foundation Competitive Research Programme (NRF-CRP); (3) the Ministry of Education Tier 3 Grant; (4) the NMRC Open Fund Large Collaborative Grant (OF-LCG); and (5) the NMRC Centre Grant. Additionally, we are supported by large philanthropic donations (>10M SGD), notably from the Goh Foundation to Proton Therapy Research, the Tibore Foundation to the Kua Hong Pak Head and Neck Cancer Research Programme, and the Singapore Rubber Miller Association to the Cancer and Data Science Programme, along with several industry support (BeiGene, Varian, MiRXES, ImmunoScape, etc.). **Collectively, as PI and Theme PI, I have secured >25M SGD of research dollars,** which support 2 key programmes:

- (1) A comprehensive nasopharyngeal carcinoma (NPC) and prostate cancer (PCa) clinical and translational research programme that leverages on innovative designs of phase II-III trials, a multi-dimensional, deeply-annotated clinical-molecular database, coupled with broad-scale computational genomics approaches for biomarker discoveries.
- (2) A translational radiation research programme that leverages on bench-to-bedside expertise to understanding the mechanistic pathways of radiation resistance (RR), and to develop new treatment regimens to target these molecular vulnerabilities.

My group has constructed tumour-specific tissue and data repositories that comprise of >2,500 patients with matched clinical and genomics data, along with longitudinal outcomes data. This invaluable resource has enabled our work to apply machine learning to develop clinical decision support tools. Citing some of our early achievements, my group has built novel prognostic tools that are ready for use in the clinic – In collaboration with the Sun Yat-Sen University Cancer Centre (SYSUCC), we have constructed several publicly available online tools, including a novel clinicomolecular risk grouping of localised NPC patients for individualised treatment strategies (**Chen FP, et al. Therapeutic Advances in Medical Oncology, 2021**); a risk prediction model for individualised selection of patients with locoregional recurrent NPC to re-irradiation (**PRANCIS: Prediction of RAdioresistant Nasopharyngeal Carcinoma Survival**; www.PRANCIS.Medlever.com; **Li YQ, et al. Journal of Clinical Oncology, 2018**); a novel phenotypic classification of patients with locoregionally-advanced NPC based on real-time tracking of treatment response with plasma cell-free EBV DNA (**Lv JW, et al. Nature Communications, 2019**). These have led to the design of 2 ongoing investigator-initiated umbrella phase II trials that investigate the efficacy of treatment intensification strategies based on early signals of response to induction chemotherapy: (1) the first is a platform trial that investigates treatment adaptation by the rapidity of EBV DNA clearance following induction chemotherapy – **EP-STAR: EPstein-barr virus DNA response to Systemic therapy for Treatment Adaptation in high-Risk nasopharyngeal carcinoma: A multi-centre, single-arm, Phase II, biomarker-guided umbrella trial**; NCT04072107; (2) the second study is another platform trial that investigates treatment individualisation by pre-treatment EBV DNA levels and EBV DNA response to induction chemotherapy – **RIBBON-LA-01: tReatment Individualisation By eBv stratificatiON in Locally Advanced nasopharyngeal carcinoma: A multi-arm platform study**; NCT05517135. The first trial has completed accrual in December 2021, and we expect results to readout in 2024. I am also the Lead Investigator of a phase III trial that will look at radiotherapy dose reduction based on induction chemotherapy response in stage II-III NPC – **REACT-IrNPC: RadiothErapy dose Adaptation by EBV DNA response to induction ChemoTherapy in Intermediate-risk NasoPharyngeal Carcinoma: A Multicentre Randomised Controlled Phase III Trial**; NCT04448522. This trial has completed enrolment of 500 patients, and is expected to read out in 2024.

My group is also involved in several early- and late-phase clinical trials investigating the use of novel therapeutics in advanced and resistant NPC. **Notably, I had led 3 landmark Phase III clinical trials that have introduced new standards-of-care NPC** – The first was testing the efficacy of induction chemotherapy and concurrent chemoradiotherapy as the new SOC for stages III-IV NPC, and here, we showed that induction gemcitabine and cisplatin improved disease control (10% at 3 years) and overall survival (5% at 3 years) in NPC patients who are at high risk of distant metastases. This seminal work was published in the New England Journal of Medicine (**Zhang Y, et al. New England Journal of Medicine, 2019**). The second trial involved investigating the role of radiotherapy to the primary tumour in patients with metastatic NPC who had responded to palliative chemotherapy. Here, we showed that the addition of local treatment reduced the risk of death by half, and delayed the onset of new distant metastases in these patients. This seminal work was published in the journal of JAMA Oncology (**You R, et al. JAMA Oncology, 2020**). The third trial looked at the efficacy and tolerability of another adjuvant regimen, specifically the use of oral capecitabine following chemoradiotherapy, in stages III-IV NPC. This trial was pivotal because adjuvant platinum-doublet chemotherapy has historically been poorly tolerated following chemoradiotherapy. Our results showed that oral capecitabine was not only well tolerated (78% compliance), but it also led to a significant improvement in disease control (13% at 5 years), thus providing physicians and patients with another treatment option. This work was also published in the journal of JAMA Oncology (**Miao JJ, et al. JAMA Oncology, 2022**). Because of my track record and involvement in several clinical trials in NPC, I was invited on the committee of international experts to draft the latest ASCO-CSCO guidelines on the treatment of locoregionally-advanced NPC, which has been published in the Journal of Clinical Oncology (**Chen YP, et al. Journal of Clinical Oncology, 2021**). All these efforts have transitioned to the clinic to influence patient's treatment outcomes.

Currently, I am the **Lead Theme PI of the Singapore NPC Large Collaborative Grant (funding quantum: 10M SGD)**, where I lead the RIBBON platform trials that will cover both locoregionally-advanced and recurrent/metastatic disease. Overall, our programme covers 3 Themes of research: (1) molecular epidemiology of NPC tumorigenesis in Singapore and the Southeast Asia region; (2) population-based screening of NPC by EBV-related assay; and (3) developing new individualised treatment strategies for NPC patients. Additionally, I sit on several advisory boards to

advise pharmaceutical companies on their pipelines for the therapeutic area of head and neck and nasopharynx cancers.

On the PCa front, my group has developed one of the largest Asian-specific repositories of PCa transcriptomes, and we have uncovered several race-specific differences in terms of molecular phenotypes, including fewer tumours with normal androgen receptor activity, a higher proportion of basal neuroendocrine tumours, and tumours harbouring an immune suppressive microenvironment. **This seminal work has been published at Cancer Communications (IF 15.283).** We are also a member of the PRACTICAL prostate cancer genomics consortia (www.PRACTICAL.icr.ac.uk), for which we have profiled and analysed the germline genome of >1,000 cases, and published in European Urology Oncology.

I also run a very active translational radiation research programme. I co-led an NRF-CRP (**funding quantum: 9.132M SGD from 2017-2022**) to investigate novel mechanisms of Proton Beam Therapy (PBT) targeting of tumours, and I was a Co-I on a Ministry of Education Tier-3 programme grant (**funding quantum: 9M SGD from 2017-2022**), in collaboration with Prof Zhang Yong, Department of Bioengineering, NUS to investigate for novel nanoparticle photo-/radio-sensitisers. Within the translational radiobiology programme, we have built deep expertise in developing *in vitro* and *in vivo* radioresistant models that mimic patients with radioresistant tumours who are seen in the clinic. Currently, our group has developed and validated a broad panel of radioresistant head and neck (NPC) and prostate cancer models. Our goals are to develop models to decipher the mechanistic pathways underpinning radioresistance, and to develop therapeutic drugs to exploit their molecular vulnerabilities. Our work has yielded several interesting discoveries, including a novel observation that cancer cells can acquire resistance to radiation through epigenomic modification of the heterochromatin DNA damage response (**Yeo C, et al. ASTRO Annual Meeting 2022, Oral Presentation; manuscript in preparation**). More excitingly, through machine learning high-throughput drug screen approaches, we have uncovered an epigenetic modifier drug that is seemingly effective in reversing the radioresistant phenotype in our cancer models (**Tan S, et al. ASTRO Annual Meeting 2022 Oral Presentation; manuscript submitted**). We are extremely excited by these results, and are exploring the possibility to translate these results to human trials; of note, some of these works were supported by the NRF-CRP and Tier 3 programme grants. Overall, the synergy between the projects contributes to the ultimate clinical goal – comprehensive patient profiling for precise risk stratification to modern therapeutic strategies.

Through my group's various programmes, we have forged several partnerships with industries (Bayer, BeiGene, Bicara Therapeutics, Janssen, Varian, etc.) and academic institutions (UCLA, University of Toronto, Manchester Cancer Research Centre, OncoRay Cancer Centre, SYSUCC etc.). I am also an ad hoc advisor to several local and global companies, including Merck, MSD, BeiGene, Bicara Therapeutics, Pfizer, Janssen, Varian, and ImmunoScape; **Of note, I am on the Global Advisory Team to advise MSD, Bicara Therapeutic, and Pfizer on their Head and Neck Cancer strategy and therapeutic portfolio.** I am also a Co-Founder of an antibody-based lateral flow diagnostic kit that has spun-off to a biotechnology company – Digital Life Line, for which I currently serve on the Board of Directors.

I am extensively involved in the leadership and membership of several committees on Head and Neck Cancer; (1) I am on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network; (2) Board representative for Singapore for the Head Neck Cancer International Group (HNCIG); (3) **Chair of the Clinical Trials Scientific Committee of HNCIG**; (4) **Chair of the NPC Expert Panel for the AJCC Staging 9th version**; (5) **UICC Representative AJCC Head and Neck Working Group for Nasopharynx Malignancy**; (6) Member of the ESTRO guidelines committee for the recommendations of post-operative radiotherapy in oral cavity cancers. My other academic activities include my present role as the Editor-in-Chief, Annals of Nasopharynx Cancer, Associate Editor of BMJ Oncology, BMC Medicine, and Journal of the National Cancer Centre, and my previous role as the Associate Senior Editor for the Head and Neck Cancer Section of the International Journal of Radiation Oncology Biology Physics – Official journal of the American Society of Radiation Oncology.

I am also an active volunteer for the American Society of Clinical Oncology (ASCO); I had previously served on the International Education Steering Group, Mentor on the inaugural APAC ASCO Leadership Development Program, and **past Council Member and Chair of the ASCO APAC Regional Council (term ended on 1 Jun 2024)**. I am also currently the **Program Chair for the ASCO Breakthrough Meeting 2024**. Additionally, I am also the **Commissioner**

representative for Singapore on the Lancet Oncology Commission on Cancer in the Commonwealth, and in 2025, I was appointed as the Commissioner for the ICRU – The International Commission for Radiation Units and Measurements. I have published over 210 peer-reviewed papers, with a H-index of 45 (>12,000 citations). I am the Lead Author of the Nasopharynx Cancer Chapter of the 12th edition of the Cancer: Principles & Practice of Oncology – the most widely-used oncology textbook worldwide, as well as other highly cited articles in the New England Journal of Medicine, Lancet, Nature, Cell, Journal of Clinical Oncology and JAMA Oncology. I was thus nominated among the World's Top 2% Most Cited Scientists in 2023 and 2024.

For my work, I have received numerous honours, including the SingHealth Excellence Distinguished Researcher Award, Conquer Cancer Foundation ASCO Merit Awards, NMRC Clinician-Scientist Award (Investigator), Fellow of the Royal College of Radiologists, Fellow of the Academy of Medicine Singapore (FAMS), and **Fellow of the American Society of Clinical Oncology**.

Peer-reviewed Grants (Total funded quantum: 70,126,801 SGD; 14,112,958 SGD for individual research)

1. **Co-I (Grant value/duration: 389,034 SGD, Dec 2023-2025)**, Bayer – Investigator Initiated Trial; *Project title: DarolutamidE + Consolidation RadiothErapy in Advanced proStatE cancer detected by PSMA (DECREASE)*
2. **PI (Grant value/duration: 683,870.42 SGD, Nov 2023-2027)**, BeiGene – Investigator Initiated Study; *Project title: tReatment Individualisation By eBv stratificatiON in Locoregionally Advanced Nasopharyngeal carcinoma: A multi-arm platform study (RIBBON-LA-01)*
3. **PI (Grant value/duration: 1,622,886.14 SGD, Sep 2023-2027)**, National Medical Research Council Clinical Trials Grant – Investigator Initiated Trial; *Project title: tReatment Individualisation By eBv stratificatiON in Locoregionally Advanced Nasopharyngeal carcinoma: A multi-arm platform study (RIBBON-LA-01)*
4. **Co-I (Grant value/duration: 91,000 SGD, Sep 2022-2024)**, Singapore Therapeutic Development Review (STDR) Pilot; *Project title: Development of a specific DDX3Y inhibitor for prostate cancer and non-Hodgkin lymphoma*
5. **Theme PI (Grant value/duration: 9,957,562 SGD, Sep 2022-2027)**, National Medical Research Council Open Fund Large Collaborative Grant; *Project title: An integrated genomic, epidemiological and intervention program for NPC early diagnosis, stratified therapeutics, and prevention*
6. **Theme PI (Grant value/duration: 20,000,000 SGD, Oct 2021-2026)**, National Medical Research Council Centre Grant; *Program title: Translating Cancer Science into Precision Care – Precise Patient, Location, Biology, Drugs and Dose*
7. **Co-I (Grant value/duration: 1,250,000 SGD, Sep 2021-2024)**, National Medical Research Council Open Fund Individual Research Grant (in collaboration with Prof Zhang Yong, Department of Bioengineering, NUS); *Project title: Combined proton beam therapy and proton beam triggered photodynamic therapy for cancer treatment*
8. **Mentor (Grant value/duration: 375,000 SGD, Sep 2021-2024)**, National Medical Research Council Transition Award 2020; *Project title: Focal Cryotherapy for Prostate Cancer: Does the Radiological-Molecular Landscape predict Oncological outcomes?*
9. **PI (Grant value/duration: 1,710,000 SGD, Sep 2021-2024)**, National Medical Research Council Clinician-Scientist Award (Investigator-category) 2020; *Project title: Germline and Somatic Mutational Correlates of Tumour Aggression and Radioresistance in Nasopharyngeal Carcinoma*
10. **PI (Grant value/duration: 1,700,000 SGD, Sep 2021-2024)**, NCCS Cancer Fund; *Project title: Kua Hong Pak Head and Neck Cancer Research Programme: Developing Precision Medicine Strategies in Head and Neck Cancers*

11. **Co-I (Grant value/duration: 1,215,700 SGD, Aug 2018-2021)**, National Medical Research Council Open Fund Individual Research Grant (in collaboration with Prof Zhang Yong, Department of Bioengineering, NUS); *Project title: Self-propelling upconversion Janus nanoparticles for overcoming light and diffusion limited penetration of drugs in solid tumours*
12. **PI (Grant value/duration: 1,275,000 SGD, Aug 2018-2021)**, National Medical Research Council Clinician-Scientist Award (Investigator-category) 2018; *Project title: Genomic and epigenomic correlates of radioresistance in nasopharynx and prostate cancers*
13. **PI (Grant value/duration: 200,000 SGD, Jun 2018-2019)**, Duke-NUS Oncology Academic Clinical Programme: Research Program of Proton Physics Fund; *Project title: To investigate Radiomics for the construction of a combinatorial clinico-radiomics model for precision proton beam therapy in nasopharynx cancer*
14. **PI (Grant value/duration: 200,000 SGD, Mar 2018-Feb 2019)**, Duke-NUS Oncology Academic Clinical Programme; *Project title: Defining systemic immune responses induced in patients post-traditional photon-based radiotherapy using high dimensional mass spectrometry and cytometry analysis*
15. **PI (Grant value/duration: 41,300 SGD, Jan 2018-Dec 2019)**, Duke-NUS Oncology Academic Clinical Programme; *Project title: Investigation of novel nanoparticle-antibody conjugates for therapeutic synergy with photon and proton therapy*
16. **PI (Grant value/duration: 170,941 SGD, Dec 2017-2018)**, Ferring Singapore Innovation Grant 2017; *Project title: To investigate germline-somatic genomic determinants of systemic metastasis and androgen sensitivity in high-risk localised prostate cancers*
17. **PI (Grant value/duration: 800,000 SGD, July 2017-2020)**, Duke-NUS Oncology Academic Clinical Programme – Proton Therapy Research Programme Fund; *Project title: Developing a radioresistance biomarker for proton therapy intensification*
18. **Theme PI (Grant value/duration: 8,615,440 SGD, June 2017-2022)**, Ministry of Education Tier 3 Programme Grant; *Program title: Remote-controlled photo-therapy with small-scale wireless bioelectronics*
19. **Theme PI (Grant value/duration: 9,130,068 SGD, June 2017-2022)**, National Research Foundation; *Program title: Radiobiology investigations into cancer therapy using high energy protons*
20. **Investigator Award (Grant value/duration: 15,000 CAD, June 2015-2016)**, Canadian Urologic Oncology Group Sanofi-sponsored Research Award 2015; *Project title: Identification of genetic determinants of clonal resistance to radiotherapy in prostate cancer; sub-proposal within the Canada Prostate Cancer Genome Network (CPC-GENE) framework*
21. **PI (Grant value/duration: 675,000 SGD, Dec 2014-Jun 2018)**, National Medical Research Council Transitional Award 2014; *Project title: Discovery of biomarkers for intrinsic radiation sensitivity in Asian patients*

Lead Principal Investigator (Clinical Trials – Ongoing)

1. **PI, RIBBON-LA-01: tReatment Individualisation By eBv stratificatiON in Nasopharyngeal carcinoma: A multi-arm platform study for locoregionally-advanced NPC (Ongoing)**
2. **PI, HARMONY: HeAd and neck Rapid deep-learning auto-segmentation tool – a Multi-clinic evaluatiON studY (Ongoing)**
3. **Co-PI, REACT-IrNPC: RadiothErapy dose Adaptation by EBV DNA response to induction ChemoTherapy in Intermediate-risk NasoPharyngeal Carcinoma: A Multicentre Randomised Controlled Phase III Trial (NCT04448522; Ongoing)**

4. **Co-PI**, A Biomarker Enrichment, Phase II study of ¹⁷⁷Lu-DOTA0-Tyr3-Octreotate in Metastatic Nasopharyngeal Cancer (Ongoing)
5. **Co-PI**, Multicentre, randomised controlled Phase III trial of adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma (NCT02143388; Ongoing)
6. **Co-PI, EP-STAR: EP**stein-barr virus DNA response to **S**ystemic therapy for **T**reatment **A**daptation in high-Risk nasopharyngeal carcinoma – A multi-centre, single-arm, Phase II, biomarker-guided umbrella trial (NCT04072107; Ongoing)
7. **PI, PROSTAR**: Phase II trial of **PRO**state **ST**ereot**ACT**ic body **R**adiotherapy for organ-confined prostate cancer (NCT02313298; Ongoing)

Lead Principal Investigator (Clinical Trials – Completed)

1. **Co-PI**, Multicentre, randomised controlled Phase III trial of locoregional radiotherapy for responders to chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (NCT02111460; Completed)
2. **Co-PI**, Multicentre, randomised controlled Phase III trial of induction gemcitabine-cisplatin and cisplatin and radiotherapy versus cisplatin and radiotherapy alone in stage 3-4 nasopharyngeal carcinoma (NCT01872962; Completed)
3. **Co-PI**, Single-arm Phase II trial of nimotuzumab in combination with cisplatin and 5-fluorouracil in recurrent/metastatic nasopharyngeal carcinoma (NCT01616849; Completed)

Clinical Trial Steering Committees

1. Pfizer ALPINE Head and Neck Cancer Developmental Program (Ongoing)
2. BCA101X301: BCA101X301 is a multicenter, randomized, placebo-controlled double-blind, seamless Phase 2/3 study comparing BCA101 versus placebo, both given in combination with pembrolizumab in subjects with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (Ongoing)
3. RIBBON-LA-01: tReatment Individualisation By eBv stratificatiOn in Nasopharyngeal carcinoma: A multi-arm platform study for locoregionally-advanced NPC (Ongoing)
4. HN-TACTIC: Towards A better paradigm for head and neck Cancer Treatment applying artificial Intelligence: an international Cohort study of electronic health records (NCT05117775; Ongoing)
5. ProstACT: ¹⁷⁷Lu-DOTA-rosopatamab with best standard of care for the second-line of treatment for metastatic castrate-resistant prostate cancer, which expresses PSMA (NCT04876651; Ongoing)
6. REACT-IrNPC: RadiothErapy dose Adaptation by EBV DNA response to induction ChemoTherapy in Intermediate-risk NasoPharyngeal Carcinoma: A Multicentre Randomised Controlled Phase III Trial (NCT04448522; Ongoing)
7. EP-STAR: EPstein-barr virus DNA response to Systemic therapy for Treatment Adaptation in high-Risk nasopharyngeal carcinoma – A multi-centre, single-arm, Phase II, biomarker-guided umbrella trial (NCT04072107; Ongoing)
8. Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma (NCT03930498; Ongoing)
9. Multicentre, randomised controlled Phase III trial of adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma (NCT02143388; Ongoing)
10. Multicentre, randomised controlled Phase III trial of locoregional radiotherapy for responders to chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (NCT02111460; Completed)

11. Multicentre, randomised controlled Phase III trial of induction gemcitabine-cisplatin and cisplatin and radiotherapy versus cisplatin and radiotherapy alone in stage 3-4 nasopharyngeal carcinoma (NCT01872962; Completed)
12. Single-arm Phase II trial of nimotuzumab in combination with cisplatin and 5-fluorouracil in recurrent/metastatic nasopharyngeal carcinoma (NCT01616849; Completed)

Lead Principal Investigator (Research)

1. **PI**, Structured research agreement with GenomeDx Biosciences (**2019-present**); *Project title: Investigation of a commercially approved molecular diagnostic test - Decipher® for risk stratification in Asian men with prostate cancer (Ongoing)*
2. **PI**, Structured research agreement with PVmed (**2019-present**); *Project title: Multicentre trial of artificial intelligence-based automated contouring in nasopharynx cancer (Ongoing)*
3. **Site PI**, PRACTICAL Prostate Consortia (**2018-present**); *Project title: PRostate Cancer Association group To Investigate Cancer Associated aLterations in the genome (PRACTICAL) (Ongoing)*
4. **PI**, Structured research agreement with Varian (**2017-2018**); *Project title: Developing a Radiomics-based signature for adaptive planning in head and neck radiotherapy (Ongoing)*
5. **PI**, Structured research agreement with MedLever (**2017-2020**); *Project title: Development of an online clinical tool for risk stratification of radioresistant nasopharynx cancers (Completed)*
6. **Co-I**, Structured research agreement with GenomeDx Biosciences (**2015-2017**); *Project title: Comparison of a DNA- and RNA-based prognostic signature in localised prostate cancer (Completed)*
7. Collaborator; *Project title: Lymphocyte chromosomal radiosensitivity and apoptosis and risk of chronic adverse effects in patients undergoing radical radiotherapy for breast and prostate cancers (Trans-FAST/CHHIP) (Completed)*

Patents and licensing

- High sensitivity lateral flow immunoassay for detection of analyte in samples (Patent no. 10202107837T), Singapore

PUBLICATIONS

Peer-reviewed Publications (First / Senior Author = 106; Total Citations = 12,227, Google scholar H-index = 45; highlighted publications in bold; <https://pubmed.ncbi.nlm.nih.gov/?term=Chua+ML&sort=date>)

1. Arbet J, Yamaguchi TN, Shiah YJ, Hugh-White R, Wiggins A, Oh J, Gebo T, Foucal A, Lesurf R, Jung CH, Dang RMA, Agrawal R, Livingstone J, Salcedo A, Yao CQ, Espiritu SMG, Houlahan KE, Yousif F, Heisler LE, Papenfuss AT, Fraser M, Pope B, Kishan A, Berlin A, **Chua ML**, et al. The Landscape of Prostate Tumour Methylation. [*In revision at Cancer Discov; IF 33.3*]
2. Lui R, Billod J, Frentzas S, ..., **Chua ML**. Understanding Barriers to Clinical Cancer Research in the Asia-Pacific - An ASCO Leadership Development Project. [*Accepted at JCO Glob Oncol; IF 3.0*]
3. **Chua ML**, et al. **Letter to the Editor on Induction vs Adjuvant Chemoradiotherapy in Patients with High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial.** [*Accepted at JAMA Oncol; IF 20.1*]
4. Chen J, Selokar A, Dominique F, Jacomina LE, Feliciano EJ, Angeline de Luna Uy J, Wu JF, Jain U, Jain B, Columbres RC, Treechirusame T, Willmann J, Ting F, Moraes FY, Gyawali B, Tangco ED, Flores JA, **Chua ML**, et al. [*Accepted at The Laryngoscope; IF 2.0*]

1. Jainar CJ, Jacomina JE, Dee EC, Lee A, Lee NY, **Chua ML**, et al. Global Disparities in Current Clinical Trials in Nasopharyngeal Carcinoma. [*Accepted at Int J Radiat Oncol Biol Phys; IF 6.4*]
2. Tang LL, Huang CL, Lin SJ, ..., **Chua ML (Co-Senior)**, et al. **Primary Target Volume Delineation for Radiotherapy in Nasopharyngeal Carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO and ASTRO Guideline and Contouring Atlas.** [*Accepted at Lancet Oncol; IF 41.6*]
3. Tang LL, Huang CL, Lin SJ, ..., **Chua ML (Co-Senior)**, et al. **Target Volume Delineation of the Neck for Radiotherapy in Nasopharyngeal Carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO and ASTRO Guideline and Contouring Atlas.** [*Accepted at Lancet Oncol; IF 41.6*]
4. Lu TZ, Xie F, Lu TJ, ..., **Chua ML (Co-Senior)**, et al. Deep Learning-based Quantification of Tumour-infiltrating Lymphocytes as a Prognostic Indicator in Nasopharyngeal Carcinoma: Multi-Cohort Findings. [*Accepted at ESMO Open; IF7.1*]
5. Tay KJ, Hong BH, Ong EH, ..., **Chua ML**. **Transcriptomic Predictors of Prostate Cancer Recurrence Following Focal Cryotherapy: A Pooled Analysis of Phase II Trial and Prospective Cohort Data.** [*Accepted at J Natl Cancer Cent; IF 7.6*]
6. Columbres RCA, Selokar A, Jones S, Wu JF, Ranganathan S, Chen J, Magsanoc NJ, Magsanoc JM, Flores JA, Feliciano EJG, Ho FDV, Moraes FY, Tangco ED, Mahal BA, Iyengar P, Nagar H, Ng K, **Chua ML**, et al. The Burden of Genitourinary Malignancies in Southeast Asia from 1990 to 2021. *Eur Urol Oncol* 2025: S2588-9311(25)00132-4. (IF 8.3)
7. Pang EPP, Tan HQ, Wang F, Niemelä J, Bolard G, Ramadan S, Kiljunen T, Capala M, Petit S, Seppälä J, Vuolukka K, Kiitam I, Zolotuhhin D, Gershkevitch E, Lehtiö K, Nikkinen J, Keyriläinen J, Mokka M, **Chua ML**. **Multicentre evaluation of deep learning CT autosegmentation of the head and neck region for radiotherapy.** *NPJ Digit Med* 2025; 8(1): 312. (IF 12.4)
8. Lin SJ, Guo QJ, Liu Q, Ng WT, Ahn YC, AlHussain H, Chan AW, Chow J, **Chua ML**, et al. **International Consensus Guideline on Delineation of the Clinical Target Volumes at Different Dose Levels for Nasopharyngeal Carcinoma (2024 Version).** *Int J Radiat Oncol Biol Phys* 2025: S0360-3016(25)00487-0. (IF 6.4)
9. Yeo EL, Yeo ELL, Hong BH, Tay SH, Neo J, Ong EHW, Chow WM, Tan KM, Low KP, Sim AYL, Lu T, Zhang X, Huang L, Tan JSH, Wee JTS, Soong YL, Fong KW, Tan TWK, Sin SY, Sam XX, Hwang JSG, Lim TKH, Lee JJ, Loo LH, Soo KC, Iyer NG, Loh KS, Tay JK, Liu J, Ang MK, Yeong JPS, Bei JX, Tan SH, Lim DWT, **Chua ML**. **Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes.** *Cell Rep Med* 2025: 102143. (IF 11.7)
10. Huang SH, Su J, Koefman SA, Routman D, Hoebbers F, Bahig H, Yu E, Bartlett E, Spreafico A, Lee J, Stock S, Davis R, Woody NM, Nelson K, Lavigne D, Nguyen-Tan PF, Létourneau-Guillon L, Filion E, Nagelschneider AA, Ma D, Van Abel KM, Postma AA, Palm WM, Hoeben A, Lydiatt W, Patel SG, **Chua ML**, et al. **A Proposal for HPV-Associated Oropharyngeal Carcinoma in the Ninth Edition Clinical TNM Classification.** *JAMA Otolaryngol Head Neck Surg* 2025: e250848. (IF 6.1)
11. **Chua ML**, et al. **Updates on Treatments and Management of Nasopharyngeal Carcinoma.** *Am Soc Clin Oncol Educ Book* 2025; 45(3): e472460. *In conjunction with ASCO Annual Meeting 2025.
12. Evans M, Bonomo P, Chan PC, **Chua ML**, et al. **Post-operative radiotherapy for oral cavity squamous cell carcinoma: Review of the data guiding the selection and the delineation of post-operative target volumes.** *Radiother Oncol* 2025; 207: 110880. (IF 4.9)
13. Neo J, Ong EHW, Zhang X, Chow WM, Wee JTS, Fong KW, Soong YL, Tan TWK, Liu J, Loh KS, Tay JK, Ang MK, Tan SH, Lim DWT, **Chua ML**. **Plasma Epstein-Barr virus DNA for disease surveillance in endemic nasopharyngeal carcinoma: Analysis of a real-world database.** *Eur J Cancer* 2025; 220: 115396. (IF 7.6)

14. Fourati N, Bacorro W, Nouri O, Agas RA, Larnaudie A, Co LB, Hammami H, Calma C, **Chua ML**, et al. International Consensus Guidelines on the Delineation of Radiation Therapy Target Volumes for Nasopharyngeal Carcinoma After Induction Chemotherapy Using a 2-Round Modified Delphi Survey. *Pract Radiat Oncol* 2025; S1879-8500(25)00019-0. (IF 3.4)
15. Blanchard P, De Felice F, **Chua ML**. Advances in individualization of systemic treatment for locoregionally advanced nasopharyngeal carcinoma: a systematic review. *ESMO Open* 2025; 10(4): 104513. (IF 7.1)
16. Shannon NB, Lyer NG, **Chua ML**. Leveraging Artificial Intelligence and Radiomics for Improved Nasopharyngeal Carcinoma Prognostication. *Cancer Med* 2025; 14(6): e70706. (IF 2.9)
17. Huang BXZ, Zhang X, Kang MP, **Chua ML**. **Personalising Nasopharyngeal Cancer: Systemic Therapy and Radiotherapy Treatment Volumes. *Semin Radiat Oncol.* 2025; 35(2): 173-89. (IF 2.6)**
18. Lee T, Sommat K, Jang I, Lim CM, Wang FQ, Soong YL, Wee J, Tan T, Fong KW, **Chua ML**, et al. Impact of Clinical Surveillance on Outcomes of Locally Recurrent Nasopharyngeal Carcinoma. *Head Neck* 2025. doi: 10.1002/hed.28060. (IF 2.4)
19. Lu T, Gao X, Yu Z, Liu L, Chen X, Xiao Y, Zhong F, Dong Q, Xie H, Tu Z, Xiong X, **Chua ML**, et al. Reducing radiation-induced hypothyroidism by modified delineation of cervical lymphatic drainage area for nasopharyngeal carcinoma treated by intensity-modulated radiation Therapy: 3 years' experience. *Radiother Oncol* 2025: 110713. doi: 10.1016/j.radonc.2025.110713. (IF 4.9)
20. Chan SPY, Yeo CPX, Hong BH, Tan EMC, Beh CY, Yeo ELL, Poon DJJ, Chu PL, Soo KC, Chua MLK, Exp Hematol Oncol. 2025 Jan 12;14(1):5. doi: 10.1186/s40164-024-00590-8. PMID: 39800760. Yeo CP, Hong BH, Tan EM, Beh CY, Yeo EL, Poon DJ, Chu PL, Soo KC, **Chua ML (Co-Senior)**, et al. **Combinatorial Functionomics Identifies HDAC6-dependent Molecular Vulnerability of Radioresistant Head and Neck Cancer. *Exp Hematol Oncol* 2025; 14(1): 5. (IF 9.4)**
21. Chong B, Saad M, Chong TW, Thng J, Tan YG, Tay KJ, Cheng C, Lin PH, Teoh J, Chiu PK, Lawrentschuk N, Eapen R, Murphy D, Chan J, **Chua ML**, et al. Selective treatment de-escalation in advanced prostate cancer: have we come full circle? *BJU Int* 2025. doi: 10.1111/bju.16632. (IF 3.7)
22. Beh CY, Yeo CPX, Hong BH, Tan EMC, Tan KM, Poon DJJ, Chu PL, Susanti D, Tai PL, Ryu M, Proudfoot J, Yeo ELL, Soo KC, **Chua ML**. **Genomic and transcriptomic profiling of radioresistant prostate and head and neck cancers implicate a BAHD1-dependent modification of DNA damage at the heterochromatin. *Cell Death Dis* 2024; 15(12): 929. (IF 8.1)**
23. Zeng Y, Luo C-L, Lin G-W, Li FG, Bai XM, Ko JM, Xiong L, Liu Y, He S, Jiang J-X, Yan W-X, Ong EH, Li Z, Zhou Y-Q, Zhou Y-H, Xu A-Y, Liu S-Q, Guo YM, Chen JR, Cheng XX, Cao YL, Yu X, Wu BH, Wei PP, Ruan ZH, Chen QY, Tang LQ, McKay JD, Jia W-H, Mai HQ, Lim ST, Liu JJ, Lin DX, Khor CC, **Chua ML (Co-Senior)**, et al. **Whole-exome sequencing association study reveals genetic effects on tumor microenvironment components in nasopharyngeal carcinoma. *J Clin Invest* 2025; 135(1): e182768. (IF 13.3)**
24. Zhang X, Yan J, Lei QQ, Neo JL, Tan SH, Shu XL, Huang L, Long B, Xie Y, Wang F, Wang YW, Tu HL, Wang CC, Zhang L, Yang JY, Zhang JW, Liu HW, Lim DW, **Chua ML (Co-Senior)**, et al. **A Randomised, Multicentre, Phase II Trial of Camrelizumab with or without Metastasis-directed Stereotactic Body Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys.* 2024; S0360-3016(24)03512-0. (IF 6.4)**
25. Gatsinga R, Tan YG, Chen W, Yang X, Tuan JKL, **Chua ML**, et al. Lost opportunities: the underutilization of castrate-resistant prostate cancer treatment in real-world settings. *Transl Androl Urol* 2024; 13(9): 1786-94. (IF 1.9)

26. Zhu HC, **Chua ML**, et al. **Global radiotherapy demands and corresponding medical professional workforce requirements: Current status and projected needs of 2050. Lancet Glob Health 2024; S2214-109X(24)00355-3. (IF 34.3)**
27. Pan JJ, Mai HQ, Ng WT, Hu CS, Li JG, Chen XZ, Chow JCH, Wong E, Lee V, Ma LY, Guo QJ, Liu Q, Liu LZ, Xu TT, Gong XC, Qiang MY, Au KH, Liu TC, Chiang CL, Xiao YP, Lin SJ, Chen YB, Guo SS, Wong CHL, Tang LQ, Xu ZY, Jia YZ, Peng WS, Hu LP, Lu TZ, Jiang F, Cao CN, Xu W, Ma J, Blanchard P, Williams M, Glastonbury CM, King AD, Patel SG, Seethala RR, Colevas AD, Fan DM, **Chua ML (Co-Senior)**, et al. **Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification. JAMA Oncol 2024. doi: 10.1001/jamaoncol.2024.4354. (IF 22.5)**
28. Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan AU, Pra AD, Ghadjar P, Sweeney CJ, Nickols NG, Karnes RJ, Shen J, Rettig MB, Czernin J, Ross AE, **Chua ML**, et al. **Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. Eur Urol 2024. S0302-2838(24)02597-1. doi: 10.1016/j.eururo.2024.09.005. (IF 25.3)**
29. Haas R, Frame G, Khan S, Neilsen BK, Hong BH, Yeo CPX, Yamaguchi TN, Ong EHW, Zhao W, Carlin B, Yeo ELL, Tan KM, Bugh YZ, Zhu C, Hugh-White R, Livingstone J, Poon DJJ, Chu PL, Patel Y, Tao S, Ignatchenko V, Kurganovs NJ, Higgins GS, Downes MR, Loblaw A, Vesprini D, Kishan AU, **Chua ML**, et al. **The Proteogenomics of Prostate Cancer Radioresistance. Cancer Res Commun 2024. doi: 10.1158/2767-9764.CRC-24-0292. (IF 2.0)**
30. Lim CY, Ng GWY, Goh CK, **Chua ML**, et al. **Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression. Oral Oncol 2024; 157: 106941. (IF 4.0)**
31. Li J-S, Blanchard P, Wong CH, Ahn YC, Bonomo P, Bresson D, Caudell J, Chen MY, Chow V, **Chua ML**, et al. **International Recommendations on Postoperative Re-irradiation for Locally Recurrent Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys 2024; S0360-3016(24)02954-7. (IF 6.4)**
32. Ang D, Chan J, Ong WS, Tan HS, Ng QS, Yuen J, Chen K, Tay KJ, Wong SW, Saad M, Nagata M, Horie S, Chansriwong P, Ng CF, Wong A, **Chua ML**, et al. **Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol 2024; 8: e2300694. (IF 4.6)**
33. Tay SB, Low GH, Wong GJE, Tey HJ, Leong FL, Li C, **Chua ML**, et al. **Use of Natural Language Processing to Infer Sites of Metastatic Disease From Radiology Reports at Scale. JCO Clin Cancer Inform 2024; 8: e2300122. (IF 4.2)**
34. Zhuang Q, Zhang AY, Cong RSTY, Yang GM, Neo PSH, Tan DS, **Chua ML**, et al. **Towards proactive palliative care in oncology: developing an explainable EHR-based machine learning model for mortality risk prediction. BMC Palliat Care 2024; 23(1): 124. (IF 3.1)**
35. Baliga S, Abou-Foul AK, Parente P, Szturz P, Thariat J, Shreenivas A, Nankivell P, Bertolini F, Biau J, Blakaj D, Brennan S, Brunet A, De Oliveira TB, Burtness B, Maseda AC, Chow VL, **Chua ML**, et al. **Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database. Eur J Cancer 2024; 203: 114038. (IF 8.4)**
36. Chiong E, Murphy DG, Buchan N, Chen K, Chen SS, **Chua ML**, et al; ANZUP Cancer Trials Group; Davis ID. **Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific Advanced Prostate Cancer Consensus Conference 2023. Asia Pac J Clin Oncol 2024. doi: 10.1111/ajco.14064. (IF 1.9)**
37. Homer JJ, Winter SC, Abbey EC, Aga H, Agrawal R, Ap Dafydd D, Arunjit T, Axon P, Aynsley E, Bagwan IN, Batra A, Begg D, Bernstein JM, Betts G, Bicknell C, Bisase B, Brady GC, Brennan P, Brunet A, Bryant V, Cantwell L, Chandra A, Chengot P, **Chua ML**, et al. **Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines, Sixth Edition. J Laryngol Otol 2024; 138(S1): S1-S224. (IF 1.1)**

38. Wang XH, Huang N, Yip PL, Wang J, Huang R, Sun Z, Kang DH, He Q, Deng XW, Zhao C, **Chua ML (Co-Senior)**, et al. **The Individualised Delineation of Clinical Target Volume for Primary Nasopharyngeal Carcinoma Based on Invasion Risk of Substructures: A Prospective, Real-world Study with a Large Population. *Radiother Oncol* 2024; 194: 110154. (IF 5.7)**
39. Tan JS, Tay TK, Ong EH, Fehlings M, Tan DS, Sukma NB, Chen EX, Sng JH, Yip CSP, Lim KH, Lim DW, Iyer NG, Hwang JS, **Chua ML (Co-Senior)**, et al. Combinatorial Hypofractionated Radiotherapy and Pembrolizumab in Anaplastic Thyroid Cancer. *Eur Thyroid J* 2024: ETJ-23-0144. (IF 4.7)
40. Yip PL, You R, Chen MY, **Chua ML**. **Embracing Personalized Strategies in Radiotherapy for Nasopharyngeal Carcinoma: Beyond the Conventional Bounds of Fields and Borders. *Cancers* 2024; 16(2): 383. (IF 5.2)**
41. Chiong E, Saad M, Hamid ARAH, Ong-Cornel AB, Lojanapiwat B, Pripatnanont C, Serrano D, Songco J, Sin LC, Hakim L, **Chua ML**, et al. Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns. *Ther Adv Med Oncol* 2024; 16: 17588359231216582. (IF 4.9)
42. Tan HQ, Cai JH, Tay SH, Sim AY, Huang L, **Chua ML (Co-Senior)**, et al. **Cluster-Based Radiomics Reveal Spatial Heterogeneity of Bevacizumab Response for Treatment of Radiotherapy-induced Cerebral Necrosis. *Comput Struct Biotechnol J* 2023; 23: 43-51. (IF 7.7)**
43. Neo JL, Yip PL, Ong EH, Miao JJ, Chow WM, Wee JT, Fong KW, Soong YL, Tan TW, Tan JS, Sin SY, Liu JJ, Loh KS, Tay JK, Ang MK, Tan SH, Lim DW, **Chua ML**. **Longitudinal Post-radiotherapy Plasma Epstein-Barr Virus DNA Trends Inform on Optimal Risk Stratification in Endemic Nasopharyngeal Carcinoma. *Oral Oncol* 2023; 148: 106655. (IF 4.8)**
44. Tay SH, Zhang X, **Chua ML**. **Radiomics in Precision Oncology: Hype or Ludum Mutante. *BMC Med* 2023; 21(1): 465. (IF 9.3)**
45. Goh D, Lim KH, Sudirman SRB, Ang MK, **Chua ML**, et al. Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report. *Chin Clin Oncol* 2023; 12(5): 57. (IF 2.8)
46. Velaga J, Tay KJ, Hang GQ, Tan YG, Yuen JS, **Chua ML**, et al. Surveillance one year post focal cryotherapy for clinically significant prostate cancer using mpMRI and PIRADS v2.1: An initial experience from a prospective phase II mandatory biopsy study. *Eur J Radiol Open* 2023; 11: 100529. (IF 2.0)
47. Naderi E, Aguado-Barrera ME, Schack LMH,... **Chua ML**, Large-Scale Meta-GWAS Reveals Common Genetic Factors Linked to Radiation-Induced Acute Toxicities across Cancers. *JNCI Cancer Spectr* 2023: pkad088. doi: 10.1093/jncics/pkad088. (IF 4.4)
48. Locati LD, Ferrarotto R, Licitra L, Benazzo M, Preda L, Farina D, Gatta G, Lombardi D, Nicolai P, Vander Poorten V, **Chua ML**, et al. Current management and future challenges in salivary glands cancer. *Front Oncol* 2023; 13: 1264287. (IF 4.7)
49. Zhang T, Wei Y, Hong BH, Sumiyoshi T, Ong EHW, Zeng H, Li Y, Ng CF, Pan J, Fang B, Wang B, Wu J, Wang H, Akamatsu S, **Chua ML (Co-Senior)**, et al. **Development and validation of a nomogram (APGRC) to predict the presence of germline DNA damage repair pathogenic variants in Asian patients with prostate cancer. *Clin Transl Med* 2023; 13(9): e1411. (IF 10.6)**
50. **Chua ML**, et al. **Transcriptomic Analyses of Localised Prostate Cancers of East Asian and North American Men Reveal Race-specific Luminal-Basal and Microenvironmental Differences. *Cancer Commun (Lond)* 2023; 43(10): 1164-8. (IF 16.2)**
51. Poh SS, Tan BF, Yong FY, Fong KW, Wee JTS, Tan TWK, **Chua ML**, et al. The impact of the COVID-19 pandemic on nasopharyngeal carcinoma patients - a national cancer centre experience. *Holist Integr Oncol* 2023; 2(1): 17.

52. Viani GA, Gouveia AG, Matsuura FK, Neves LVF, Marta GN, **Chua ML**, et al. Assessing the efficacy of palliative radiation treatment schemes for locally advanced squamous cell carcinoma of the head and neck: a meta-analysis. *Rep Pract Oncol Radiother* 2023; 28(2): 137-46. (IF 1.2)
53. Tan RSYC, Lin Q, Low GH, Lin R, Goh TC, Chang CCE, Lee FF, Chan WY, Tan WC, Tey HJ, Leong FL, Tan HQ, Nei WL, Chay WY, Tai DWM, Lai GGY, Cheng LT, Wong FY, Chua MCH, **Chua ML**, et al. Inferring cancer disease response from radiology reports using large language models with data augmentation and prompting. *J Am Med Inform Assoc* 2023: ocad133. doi: 10.1093/jamia/ocad133. (IF 7.942)
54. Yang X, Tan YG, Gatsinga R, Chen W, Huang HH, Loong JTK, **Chua ML**, et al. Far from the truth: Real-world treatment patterns among newly diagnosed metastatic prostate cancer in the era of treatment intensification. *Int J Urol* 2023. doi: 10.1111/iju.15243. (IF 2.896)
55. Akimoto T, Aoyama H, **Chua ML**, et al. Challenges and Opportunities With the Use of Hypofractionated Radiation Therapy in Cancer Care: Regional Perspectives From South Korea, Japan, Singapore, and Australia. *Adv Radiat Oncol*. 2023 Jun 14;8(6):101291. (IF 4.5)
56. Yip PL, Lee AW, **Chua ML**. **Adjuvant Chemotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. *Lancet Oncol* 2023; S1470-2045(23)00266-8. doi: 10.1016/S1470-2045(23)00266-8. (IF 54.433)**
57. Berlin A, Ramotar M, Santiago AT, Liu Z, Li J, Wolinsky H, Wallis CJD, **Chua ML**, et al. **The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. *J Natl Cancer Inst* 2023; djad108. doi: 10.1093/jnci/djad108. (IF 11.816)**
58. Petit C, Lee A, Ma J, Lacas B, et al.; **MAC-NPC Collaborative Group. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. *Lancet Oncol* 2023; 24(6): 611-23. (IF 54.433)**
59. Desai NB, Dal Pra A, **Chua ML**, et al. Passing the Kool-Aid Point: mRNA Expression-Based Risk Classifiers in Localized Prostate Cancer Treatment Decision Making. *Int J Radiat Oncol Biol Phys* 2023; 116(3): 530-2. (IF 8.013)
60. Weiner AB, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, Zhang JH, Li EV, Karnes RJ, Den RB, Kishan AU, Reiter RE, Hamid AA, Ross AE, Tran PT, Davicioni E, Spratt DE, Attard G, Lotan TL, **Chua ML**, et al. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. *Cancer* 2023; 129(14): 2169-78. (IF 6.2)
61. Kanesvaran R, Chia PL, Chiong E, **Chua ML**, et al. **An Approach to Genetic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Singapore. *Ann Acad Med Singap* 2023; 52(3): 135-48. (IF 8.713)**
62. Tan YG, Law YM, Ngo NT, Khor LY, Tan PH, Ong EH, Yuen JS, Ho HS, Tuan JK, Kanesvaran R, Gupta R, Rozen S, **Chua ML**, et al. Patient-reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A phase II mandatory biopsy-monitored study. *Prostate* 2023; 83(8): 781-91. (IF 4.104)
63. Lim DW, Kao H-F, Suteja L, Li CH, Quah HS, Tan DS, Tan SH, Tan EH, Tan WL, Lee JN, Ting FW, Jain A, Goh BC, **Chua ML**, et al. **Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma. *Nat Commun* 2023; 14(1): 2781. (IF 17.69)**
64. Miao JJ, Wang L, Ong EH, Hu CS, Lin SJ, Chen XZ, Chen YY, Zhong YH, Jin F, Lin Q, Lin SM, Hu XF, Zhang N, Wang RS, Wang C, Guo X, Yit NL, Shin HP, Tan SH, Mai HQ, Xie CH, **Chua ML (Co-Senior)**, et al. **Effects of Induction Chemotherapy on Nutrition Status in Locally-advanced Nasopharyngeal Carcinoma: A Multicenter Prospective Study. *J Cachexia Sarcopenia Muscle* 2023; 14(2): 815-25. (IF 12.063)**

65. **Chua ML**, et al. **Hyperfractionation for re-irradiation of recurrent nasopharyngeal carcinoma. Lancet 2023; 401(10380): 878-9. (IF 202.7)**
66. **Chua ML**, et al. Management of the neck in nasopharyngeal carcinoma-time for a radical change? Chin Clin Oncol 2023; 12(1): 8. (IF 2.8)
67. Cheng J, Jiang J, He B, Lin WJ, Li Y, Duan J, Li H, Huang X, Cai J, Xie J, Zhang Z, Yang Y, Xu Y, Hu X, Wu M, Zhuo X, Liu Q, Shi Z, Yu P, Rong X, Ye X, Saw PE, Wu LJ, Simone CB 2nd, **Chua ML**, et al. **A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury. Sci Transl Med 2023; 15(684): eabm6543. doi: 10.1126/scitranslmed.abm6543. (IF 19.319)**
68. Lam JW, King AD, Miller JA, Liu ZW, Yu KJ, **Chua ML**, et al. **Recommendations for Epstein-Barr virus-based screening and management for the early detection of nasopharyngeal cancer in high- and intermediate-risk regions. J Natl Cancer Inst 2023; 115(4): 355-64. (IF 11.816)**
69. de Guzman RB, **Chua ML**, et al. **ASCO's Leadership Development Program: Focusing on the Next Generation of Leaders in Asia Pacific. JCO Glob Oncol 2023; 9: e2200313. doi: 10.1200/GO.22.00313. (IF 4.5)**
70. Chia BSH, Ho SZ, Tan HQ, **Chua ML**, et al. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel) 2023; 15(2): 346. (IF 6.565)
71. Park SH, Hong SH, Kim K, Lee SW, Yon DK, Jung SJ, Abdeen Z, Brahim Ahmed MLC, Serouri AA, Al-Herz W, Subbaram K, Shaik Syed P, Ali S, Ali K, Al-Shamsi HO, Baatarkhuu O, Nielsen HB, Bernini-Carri E, Bondarenko A, Cassell A, Cham A, **Chua ML**, et al. **Non-Pharmaceutical Interventions Reduce the Incidence, and Mortality of COVID-19: A Study based on the Survey from the International COVID-19 Research Network (ICRN). J Med Virol 2023; 95(2): e28354. (IF 20.693)**
72. Yeo BS, Muhammad HJ, Song D, Soong YL, **Chua ML**, et al. Efficacy of Anti-PD1 Blockage in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-Analysis. Oral Oncol 2022; 136: 106242. (IF 5.972)
73. Naderi E, Schack LMH, Welsh C, Sim AYL, Aguado-Barrera ME, Dudding T, Summersgil H, Martínez-Calvo L, Ong EHW, Odding Y, Varela-Pazos A, Steenbakkens RJHM, Crijns APG, Jena R, Pring M, Dennis J, Lobato-Busto R, Alsner J, Ness A, Nutting C, Thomson DJ, Gómez-Caamaño A, Eriksen JG, Thomas SJ, Bates AM, Overgaard J, Cascallar-Caneda LM, Duprez F, Barnett GC, Dorling L, **Chua ML**, et al. Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer. Radiother Oncol 2022; 176: 138-48. (IF 6.901)
74. Ng WT, But B, Wong C, Choi CW, **Chua ML**, et al. Particle beam therapy for nasopharyngeal cancer: a systematic review and meta-analysis. Clin Transl Radiat Oncol 2022; 37: 41-56. (IF 4.739)
75. Miao JJ, Wang L, Tan SH, Li JG, Yi JL, Ong EH, Tan LL, Zhang Y, Gong XC, Chen QY, Xiang YQ, Chen MY, Guo Y, Lv Xing, Xia WX, Tang LQ, Deng XW, Guo X, Han F, Mai HQ, **Chua ML (Co-Senior)**, et al. **Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally-advanced nasopharyngeal carcinoma: a randomized controlled trial. JAMA Oncol 2022; 8(12): 1776–85. (IF 33.01)**
76. Murgić J, Fröbe A, **Chua ML**. Recent Advances in Radiotherapy Modalities for Prostate Cancer. Acta Clin Croat 2022; 61(Suppl 3): 57-64. (IF 0.932)
77. Pan D, Rong XM, Chen DP, Jiang JR, Ng WT, Mai HQ, Li Y, Li HH, Cai JH, Cheng JP, Xu YT, Chua ML, et al. **Mortality of early treatment for radiation-induced brain necrosis in head and neck cancer survivors: a multicenter, retrospective, registry-based cohort study. EClinicalMedicine 2022; 52: 101618. (IF 17.033)**

78. Yang XY, Carson JA, Aslim EJ, Tay K-J, Yuen JS, Kanesvaran R, **Chua ML**, et al. Patient-Reported outcomes of a phase II Neoadjuvant Apalutamide (ARN-509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer (NEAR) trial. *Int J Urol* 2022 Aug 24. doi: 10.1111/iju.14994. (IF 2.896)
79. **Chua ML**. Stochastic Stomatitis: Radiation-recall reactions in the era of immune checkpoint blockade. *Int J Radiat Oncol Biol Phys* 2023; 115(1): 9. (IF 8.013)
80. Lee NY, Hum M, Ong PY, Myint MK, Ong EHW, Low KP, Li Z, Goh BC, Tay JK, Loh KS, **Chua ML**, et al. Germline Variants Associated with Nasopharyngeal Carcinoma Predisposition Identified through Whole-Exome Sequencing. *Cancers (Basel)* 2022; 14(15): 3680. (IF 6.575)
81. Kanesvaran R, Castro E, Wong A, Fizazi K, **Chua ML**, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with prostate cancer. *ESMO Open* 2022; 7(4): 100518. (IF 6.883)
82. Eala MA, Dee EC, Ginsburg, **Chua ML**, et al. Financial toxicities of cancer in low- and middle-income countries: perspectives from Southeast Asia. *Cancer* 2022 Jun. doi: 10.1002/cncr.34353. (IF 6.921)
83. McDowell L, **Chua ML**, et al. A bit more here and a little less there: the trials (and tribulations) of adjuvant and neoadjuvant head and neck studies in 2021. *Int J Radiat Oncol Biol Phys*. 2022 Jun 1;113(2):243-251. (IF 8.013)
84. He L, Pi YX, Li Y, Wu Y, Rong XM, Jiang JR, Cai JH, Cheng JP, Li HH, **Chua ML**, et al. Efficacy and safety of apatinib in radiation-induced brain injury: an open-label, single-arm, external controlled, phase 2 study. *Int J Radiat Oncol Biol Phys* 2022 Apr. doi: 10.1016/j.ijrobp.2022.03.027. (IF 8.013)
85. Li YQ, Ong WS, Ma TTS, Quek SZ, Pang EP, Looi WS, Nei WL, Wang ML, **Chua ML**, et al. Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study. *Cardio-Oncology* 2022 Mar. doi: 10.1186/s40959-022-00131-4.
86. Ng WT, **Chua ML**, et al. **Identifying Patients with ‘Low-risk’ Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma EBV DNA for Chemotherapy De-intensification: Quo Vadis? J Clin Oncol 2022; 40(11): 1135-8. (IF 50.717)**
87. Ng WT, **Chua ML**, et al. **Maintenance capecitabine in recurrent metastatic nasopharyngeal carcinoma: Magic bullet or pandora’s box? JAMA Oncol 2022; 8(4): 524-5. (IF 33.01)**
88. Chiong E, Murphy DG, Buchan NC, **Chua ML**, et al. Managing advanced prostate cancer in the Asia Pacific region: ‘real world’ application of Advanced Prostate Cancer Consensus Conference 2019 statements. *Asia Pac J Clin Oncol* 2022 Feb. doi: 10.1111/ajco.13722. (IF 1.926)
89. Dee EC, Eala MA, **Chua ML**, et al. Adolescents and young adults with cancer: considerations from the Southeast Asian perspective. *Pediatr Blood Cancer* 2022 Feb: e29593. doi: 10.1002/pbc.29593. (IF 3.838)
90. Han ST, Zhuang QY, Chiang JB, Tan SH, Chua GW, Xie CH, **Chua ML**, et al. Impact of cancer diagnoses on the outcomes of patients with COVID-19 – a systematic review and meta-analysis. *BMJ Open* 2022; 12(2): e044661. (IF 3.006)
91. Lee LS, Sim AYL, Ong CW, Yang X, Ng CCY, Liu W, Rajasegaran V, Lim AMS, Aslim EJ, Ngo NT, Khor LY, Kanesvaran R, Allen JCJ, Tay KJ, Yuen JSP, Chong TW, Ho SSH, Teh BT, **Chua ML**. **NEAR trial: A Single-arm Phase II trial of Neoadjuvant Apalutamide and Radical Prostatectomy in D’Amico-defined Intermediate- and High-risk Prostate Cancer. Prostate Cancer Prostatic Dis 2022; 25(4): 741-8. (IF 5.455) *Editors’ choice of Best of 2022 in prostate cancer and prostate diseases**
92. Schack LMH, Naderi E, Fachal L, Dorling L, Luccarini C, Dunning AM; Head and Neck Group of the Radiogenomics Consortium; Danish Head and Neck Cancer Group (DAHANCA), Ong EHW, **Chua ML**, et al.

A Genome Wide Association Study of Radiotherapy-induced Toxicity in Head and Neck Cancer Patients identifies a Susceptibility Locus Associated with Mucositis. *Br J Cancer* 2022 Jan. doi: 10.1038/s41416-021-01670-w. (IF 7.64)

93. Tang S-Q, Chen L, Li W-F, Chan AT, Huang SH, **Chua ML**, et al. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9,468 cases and validation by two phase 3 trials. *Radiother Oncol* 2021; 167: 179-86. (IF 6.28)
94. Tan LL, Quynh LT, Lee N, **Chua ML**. **JUPITER-02: Advancing survival in recurrent metastatic nasopharyngeal carcinoma and next steps.** *Cancer Commun (Lond)* 2021 Jan. doi: 10.1002/cac2.12248. (IF 15.283)
95. Chong LM, Tng DJ, Tan LL, **Chua ML (Co-senior)**, et al. **Recent advances in radiation therapy and photodynamic therapy.** *Applied Physics Reviews* 2021; 8 (4): doi.org/10.1063/5.0060424. (IF 19.162)
96. Tan JS, Teh JY, Tan LL, Tan SX, Li YQ, Tan TW, Wang ML, Kanesvaran R, Ong EH, Tay K-J, Lee LS, Tuan JK, Tan DY, **Chua ML**. **Efficacy, Toxicity and Quality-of-Life Outcomes of Ultrahypofractionated Radiotherapy in Patients with Localised Prostate Cancer: a Single-arm Phase 2 Trial from Asia.** *Asia Pac J Clin Oncol* 2021 Dec. doi: 10.1111/ajco.13742. (IF 2.601)
97. Ng WT, Choi H, **Chua ML**, et al. Letter in response to Abbasi et al. on International Recommendations on Re-irradiation by Intensity-modulated Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys* 2022; 112(1): 262-3 (IF 7.04)
98. Tng DJH, Yin BCY, Cao J, Ko KKK, Goh KCM, Chua DXW, Zhang Y, **Chua ML**, et al. **Amplified Parallel Antigen Rapid Test for Point-Of-Care Salivary Detection of SARS-CoV-2 with improved sensitivity.** *Mikrochim Acta* 2021; 189(1): 14. (IF 5.833)
99. Lee AY, Tiwari R, Neo SH, Huned D, Kumaran A, Lim CL, **Chua ML**, et al. The uro-oncology multi-disciplinary team (MDT) clinic – clinical and patient-reported outcomes from implementing a new model of care. *Proceedings of Singapore Healthcare* 2021; 1-5.
100. Teng YH, Quah HS, Suteja L, Dias JM, Mupo A, Bashford-Rogers RJ, Vassiliou GS, **Chua ML**, et al. Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures. *Cancer Immunol Immunother* 2021: 1–10. (IF 6.968)
101. Blanchard P, Lee AW, Carmel A, Wai Tong N, Ma J, Chan AT, Hong RL, Chen MY, Chen L, Li WF, Huang PY, Kwong DL, Poh SS, Ngan R, Mai HQ, Ollivier C, Fountzilias G, Zhang L, Bourhis J, Aupérin A, Lacas B, Pignon JP; **MAC-NPC collaborative Group. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients.** *Clin Transl Radiat Oncol* 2021; 32: 59-68. (IF 3.405)
102. Chen FP, Zhou GQ, Luo YS, Tan LK, Tan SH, Zheng Y, Lin L, Lv J-W, Kou J, Huang X-D, Zheng Z-Q, He X-J, Wu C-F, Zhang L-L, Zhu B-T, He X-Y, Ma J, Guo Y, **Chua ML (Co-senior)**, et al. **Development of a Clinicomolecular Risk Stratification System for Non-metastatic Nasopharyngeal Carcinoma using Epstein–Barr virus DNA and TNM Stage in 9,160 endemic cases from Southern China.** *Ther Adv Med Oncol* 2021; 13: 17588359211052417. (IF 8.168)
103. Li HH, Rong XM, Hu WH, Yue ZW, Huang XL, **Chua ML**, et al. Bevacizumab combined with corticosteroid do not improve the clinical outcome of radiation-induced brain necrosis: a real world data from a registry cohort. *Front Oncol* 2021; 11: 746941. (IF 6.244)
104. Emanuel O, Liu J, Schartinger V, Nei WL, Chan YY, Tsang CM, Riechelmann H, Masterson L, Oppermann U, Willems SM, Ooft ML, Wollmann G, Howard D, Vanhaesebroeck B, Lund VJ, Royle G, **Chua ML**, et al. SSTR2 in nasopharyngeal carcinoma: relationship with latent EBV infection and potential as a therapeutic target. *Cancers (Basel)* 2021; 13(19): 4944. (IF 6.639)

105. Ramotar M, **Chua ML**, et al. Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. *Urol Oncol* 2021; S1078-1439(21)00376-8. (IF 3.498)
106. Sin SY, **Chua ML**, et al. An evaluation of concordance between Head and Neck Advanced Practice Radiation Therapist and Radiation Oncologists in toxicity assessment for nasopharyngeal carcinoma patients. *Tech Innov Patient Support Radiat Oncol* 2021; 19: 52-6.
107. Chua KL, Chu PL, Tng DJ, Soo KC, **Chua ML**. Repurposing Proton Beam Therapy through Novel Insights of Tumour Radioresistance. *Clin Oncol* 2021; 33(11): e469-81. (IF 4.126)
108. YQ Li, TK Chan, SQ Zhou, JH Yap, EP Pang, AL Ong, ML Wang, **Chua ML**, et al. A comparative analysis between low dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men. *Acta Oncol* 2021: 1-5. (IF 3.701)
109. Mierzwa M, Beadle B, **Chua ML**, et al. Something for Everyone from Low-Risk to High-Risk: Five Recent Studies to Improve Treatment and Surveillance for All Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN). *Int J Radiat Oncol Biol Phys* 2021; 111(1): 1-8. (IF 7.04)
110. Poh SS, Soong YL, Sommat K, Lim CM, Fong KW, Tan TW, **Chua ML**, Wang FQ, Hu J, Wee JT. **Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives. *Cancer Commun (Lond) 2021; 41(5): 361-70. (IF 15.283)***
111. Carsuzaa F, Lapeyre M, Gregoire V, Maingon P, Beddok A, Marcy P-Y, Salleron J, Coutte A, Racadot S, Pointreau Y, Graff P, Beadle B, Benezery K, Biau J, Calugaru V, Castelli J, **Chua ML**, et al. Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: a GORTEC internationally reviewed HNCIG-endorsed consensus. *Radiother Oncol* 2021; 160: 140-7. (IF 6.28)
112. Poon JD, Tay LM, Ho D, **Chua ML (Co-senior)**, et al. **Improving the therapeutic ratio of radiotherapy against radioresistant cancers: leveraging on novel artificial intelligence-based approaches for drug combination discovery. *Cancer Lett 2021; 511: 56-67. (IF 8.679)***
113. **Chua ML**, et al. **Surgery for the management of locoregionally-advanced nasopharyngeal carcinoma: One-size-fit-all approach? *Lancet Oncol 2021; 22(6): e217. (IF 41.316)***
114. Ng WT, Soong YL, Ahn YC, AlHussain H, Choi HC, Corry J, Gregoire V, Harrington KJ, Hu CS, Jensen K, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Pan JJ, Peters LJ, Poh SS, Rosenthal DI, Sanguineti G, Tao YG, Wee JT, Yom SS, **Chua ML (Co-senior)**, et al. **International Recommendations on Re-irradiation by Intensity-modulated Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys 2021; 110(3): 682-95. (IF 7.04)***
115. Huang L, Zhang X, Bai Y, Chua KLM, Xie Y, Shu X, Long B, Fan C, Lim DWT, Tan SH, Wee JTS, Wang Y, Wu Y, **Chua ML**. Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study. *Oral Oncol* 2021; 115: 105222. (IF 5.337)
116. Karam SD, Anderson CM, Ma D, **Chua ML**, et al. Immunotherapy in head and neck cancer - ready for prime time or more research needed? *Int J Radiat Oncol Biol Phys* 2021; 109(3): 647-50. (IF 7.04)
117. Karlsson Q, Karlsson Q, Brook MN, Dadaev T, Wakerell S, Saunders EJ, Muir K, Neal DE, Giles GG, MacInnis RJ, Thibodeau SN, McDonnell SK, Cannon-Albright L, Teixeira MR, Paulo P, Cardoso M, Huff C, Li D, Yao Y, Scheet P, Permuth JB, Stanford JL, Dai JY, Ostrander EA, Cussenot O, Cancel-Tassin G, Hoegel J, Herkommer K, Schleutker J, Tammela TLJ, Rathinakannan V, Sipeky C, Wiklund F, Grönberg H, Aly M, Isaacs WB, Dickinson JL, FitzGerald LM, **Chua ML**; PRACTICAL Consortium, et al. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. *Eur Urol Oncol* 2021: S2588-9311(20)30209-1. (IF 8.208)

118. Chen YP, Ismaila N, **Chua ML**, et al. **Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage II to IVA Nasopharyngeal Carcinoma: Chinese Society of Clinical Oncology and American Society of Clinical Oncology Guideline.** *J Clin Oncol* 2021; 39(7): 840-59. (IF 44.544)
119. Berlin A, Lovas M, Truong T, Melwhani S, Liu J, Liu ZH, Badzynski A, Carpenter MB, Virtanen C, Morley L, Bhattacharyya O, Escaf M, Moody L, Brzozowski L, **Chua ML**, et al. **Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19.** *JAMA Oncol* 2021; 7(4): 597-602. (IF 31.777)
120. Lechner M, Schartinger VH, Steele CD, Nei WL, Ooft ML, Schreiber L-M, Pipinikas CP, Chun GT, Chan YY, Wu F, To KF, Pearce W, Morelli D, Philpott M, Masterson L, Nibhan R, Wells G, Bell CG, Koller J, Delecluse S, Yip YL, Forde CT, Forster MD, Jay A, Dudás J, Krapp A, Wan S, Uprimny C, Sprung S, Fenton TR, Chester K, Thirlwell C, Indrasari SR, Herdini C, Mohd Slim MA, Sutton L, Fles R, Tan B, Yeong J, Jain A, Wang H-T, Loke KS, He W, Xu RL, Jin HT, Cheng ZQ, Howard D, Hwang PH, Le QT, Tay JK, West RB, Tsao SW, Meyer T, Riechelmann H, Oppermann U, Delecluse H-J, Willems SM, **Chua ML**, et al. **Key role of Somatostatin receptor 2 in nasopharyngeal cancer and its association with EBV: impact on prognosis, imaging and therapy.** *Nat Commun* 2021; 12(1): 117. (IF 17.69)
121. Kilijunen T, Akram S, Niemela J, Seppala J, Heikkila J, Vuolukka K, Kaariainen O-S, Heikkila V-P, Lehtio K, Nikkinen J, Gerskevits E, Borkvel A, Adamson M, Zolotuhhin D, Kolk K, Pang E, Tuan JT, Master Z, **Chua ML**, et al. A deep learning-based automated CT segmentation of prostate cancer anatomy for radiation therapy planning – a retrospective multicentre study. *Diagnostics (Basel)* 2020; 10(11): 959. (IF 3.110)
122. Huang L, Sim AY, Wu YZ, Liang ZG, Li KG, Du YQ, Ong EH, Tan HQ, Wee JT, Xie Y, Shu XL, Wang Y, **Chua ML (Co-senior)**, et al. Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma. *Ther Adv Med Oncol* 2020; 12: 1758835920970050. (IF 8.168)
123. Wu QJ, Zhang HY, Zhong Y, **Chua ML (Co-senior)**, et al. Reply to Colorectal cancer and COVID-19: Do we need to raise awareness and vigilance? *Cancer* 2021; 127(6): 980-1. (IF 5.742)
124. Tan LL, **Chua ML**. Discovering Biomarkers of Radioresistance in a Radiosensitive Cancer: A Clinical Paradox in Nasopharyngeal Carcinoma. *Ann Transl Med* 2020; 8(20): 1284. (IF 3.297)
125. Chia BS, Leong JY, Ong AL, Lim C, Poon SH, **Chua ML**, et al. Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol. *BMC Cancer* 2020; 20(1): 1045. (IF 3.150)
126. Curigliano G, Banerjee S, Cervantes A, et al.; **Panel members.** **Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.** *Ann Oncol* 2020; 31(10): 1320-35. (IF 32.98)
127. Tan HQ, Koh WY, Yeo EL, Ang KW, Poon DJ, Lim CP, Vajandar SK, Chen CB, Ren M, Osipowicz T, Soo KC, **Chua ML**, et al. Dosimetric Uncertainties Impact on Cell Survival Curve with Low Energy Proton. *Phys Med* 2020; 76: 277-84. (IF 2.485)
128. Xie CH, Wang XY, Liu H, Bao ZR, Yu J, Zhong YH, Wang XH, **Chua ML.** **Outcomes of Cancer Patients undergoing Radiotherapy during the COVID-19 Outbreak in Wuhan, China.** *JAMA Oncol* 2020; 6(9): 1457-9. (IF 31.777)
129. Cai JH, Zheng JJ, Shen J, Yuan ZY, Xie MW, Gao MM, Tan HQ, Liang ZG, Rong XM, Li Y, Li HH, Jiang JR, Zhuo XH, Argyriou AA, **Chua ML**, et al. **A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy.** *Clin Cancer Res* 2020; 26(20): 5438-47. (IF 12.53)
130. You R, Liu Y-P, Huang P-Y, Xiong Z, Sun R, He Y-X, Wu Y-S, Shen G-P, Zhang H-D, Duan C-Y, Tan SH, Cao J-Y, Li J-B, Xie Y-L, Zhang Y-N, Wang Z-Q, Yang Q, Lin M, Jiang R, Zhang M-X, Hua Y-J, Tang L-Q, Luo D-H, Chen Q-Y, Mo H-Y, Guo L, Chen Y, Mai HQ, Zhang L, Ling L, Liu Q, **Chua ML (Co-senior)**, et al. **Comparison**

of chemotherapy plus locoregional radiotherapy with chemotherapy alone in primary metastatic nasopharyngeal carcinoma: a randomized, open-label, phase 3 trial. JAMA Oncol 2020; 6(9): 1345-52. (IF 31.777)

131. Wu QJ, Chu Q, Zhang HY, Yang B, He XD, Zhong YH, Yuan XL, **Chua ML (Co-senior)**, et al. **Clinical outcomes of 2019 Novel Coronavirus Disease (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors. Cancer Commun (Lond) 2020; 40(8): 374-9. (IF 10.392)**
132. Huang X, Zhang X, Wang X, Rong X, Li Y, Li H, Jiang J, Cai J, Zhuo X, Pi Y, Lin J, **Chua ML**, et al. A nomogram to predict symptomatic epilepsy in patients with radiation-induced brain necrosis. *Neurology* 2020; 95(10): e1392-e1403. (IF 8.770)
133. **Chua ML**, et al. **Letter in reply: SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan. JAMA Oncol 2020; 6(9): 1472-3. (IF 31.777)**
134. Brastianos HC, Murgic J, Salcedo A, **Chua ML**, et al. Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. *Eur Urol Oncol* 2020: S2588-9311(20)30083-3. (IF 7.479)
135. Zhang HY, Wang LW, Chen YY, Shen XK, Wang Q, Yan YQ, Yu Y, Zhong YH, **Chua ML (Co-senior)**, et al. Outcomes of Novel Coronavirus Disease 2019 (COVID-19) Infection in 107 Patients With Cancer From Wuhan, China. *Cancer* 2020; 126(17): 4023-31. (IF 5.742)
136. Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhurairi A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, **Chua ML**, et al. Authors Reply: Evolution of Cancer Care in Response to the COVID-19 Pandemic. *Oncologist* 2020; 25(9): e1426-7. (IF 5.550)
137. Chua KL, Fehlings M, Chu PL, Yeo EL, Nardin A, Sumatoh H, Nei WL, Ong EH, Woo WY, Low KP, Wang HT, Poon DJ, Liang ZG, Yao K, Luo H, Toh CK, Ang MK, Farid M, Kanesvaran R, Dent R, Wee JT, Iyer NG, Tan DS, Soo KC, Newell EW, **Chua ML**. **High-dimensional characterization of the systemic immune landscape informs on synergism between radiotherapy and immune checkpoint blockade. Int J Radiat Oncol Biol Phys 2020; 108(1): 70-80. (IF 7.04)**
138. Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhurairi A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, **Chua ML**, et al. Authors Reply: How to manage febrile neutropenia during the COVID pandemic? In response to, "A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic. *Oncologist* 2020; 25(6): e936-45. (IF 5.550)
139. **Chua ML**, et al. Follow-up and management of head and neck cancer patients during the 2019 novel coronavirus (SARS-CoV-2) disease pandemic. *Adv Radiat Oncol* 2020; 5(4): 631-6. (IF 2.65)
140. Al-Shamsi HO, Alhazzani W, Alhurairi A, Coomes EA, Chemaly RF, Almuhanna M, Wolff R, Nuhad IK, **Chua ML**, et al. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. *Oncologist* 2020; 25(6): e936-45. (IF 5.550)
141. Miao JJ, Di MP, Chen BY, Wang L, Cao YQ, Xiao WW, Wong KH, Luo H, Zhu MY, Huang HG, Huang SM, Han F, Deng XW, Xiang YQ, Lv X, Xia WX, Tan SH, Wee JT, Guo X, **Chua ML (Co-senior)**, et al. **A prospective 10-year observational study of reduction of radiotherapy clinical target volume and dose in early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2020; 107(4): 672-82. (IF 7.04)**
142. Yu J, Ouyang W, **Chua ML (Co-senior)**, et al. **SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan. JAMA Oncol 2020; 6(7): 1108-10. (IF 31.777)**
143. Guo Y-M, Chen J-R, Feng Y-C, **Chua ML (Co-first)**, et al. **Germline polymorphisms and length of survival of nasopharyngeal carcinoma: An exome-wide association study in multiple cohorts. Adv Sci (Weinh) 2020; 7(10): 1903727. (IF 16.80)**

144. Luo H, **Chua ML**. **Surgery as an alternative to radiotherapy in early-stage nasopharyngeal carcinoma – Innovation at the expense of uncertainty. *Cancer Commun (Lond)* 2020; 40(2-3): 119-21. (IF 10.392)**
145. Margalit DN, Karam SD, **Chua ML**, et al. Four influential clinical trials of human papilloma virus-associated oropharynx cancer. *Int J Radiat Oncol Biol Phys* 2020; 106(5): 893-9. (IF 7.04)
146. Masterson L, Howard J, Gonzalez-Cruz J, Jackson C, Barnett C, Overton L, Liu H, Ladwa R, Simpson F, McGrath M, Wallwork B, Jones T, Ottensmeier C, **Chua ML**, et al. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: beyond an era of chemoradiation? *Int J Cancer* 2020; 146(8): 2305-14. (IF 5.145)
147. Hou WL, Chen Q, Wang HT, Qiu PX, Lye XY, Chen WP, **Chua ML**, et al. The metabolic footprint during adipocyte commitment highlights ceramide modulation as an adequate approach for obesity treatment. *EBioMedicine* 2020; 51: 102605 (IF 5.736)
148. Rangabashyam M, Wee HE, Wang WN, Mueller S, Karim KA, Skanthakumar T, Hariraman B, Sommat K, Soong YL, **Chua ML**, et al. Electronic Tumor Board Presentations as the Basis for the Development of a Head and Neck Cancer Database. *Laryngoscope Investig Otolaryngol* 2020; 5(1): 46-54.
149. Pang EP, Knight K, Park SY, Lian WX, Master Z, Baird M, Chan JW, Wang ML, Tan TW, **Chua ML**, et al. Duration-dependent margins for prostate radiotherapy - a practical, low-cost, motion mitigation strategy. *Strahlenther Onkol* 2020; 196(7): 657-63. (IF 2.899)
150. Liu L-T, **Chua ML**, et al. **Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma. *Cancer Commun* 2019; 39(1): 64. (IF 10.392)**
151. Glicksman RM, Tjong MC, Neves-Junior WF, Spratt DE, Chua KC, Mansouri A, **Chua ML**, et al. **Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review and Synthesis for the Modern Oncologist. *JAMA Oncol* 2020; 6(4): 567-77. (IF 31.777)**
152. **Chua ML**, Ying S, Supiot S. Advances in Nasopharyngeal Carcinoma – “West meets East”. *Br J Radiol* 2019; 92(1102): 20199004. (IF 2.196)
153. Chan J, Ching FY, Chi JL, Toh CK, Ng QS, Rajasekaran T, **Chua ML**, et al. Real-world clinical experience with Abiraterone Acetate plus Prednisone/Prednisolone: The Singapore Experience. *Asia Pac J Clin Oncol* 2020; 16(1): 75-9. (IF 2.601)
154. Liang Z-G, Zhang F, Tan LK, Lin L, Lenkowitz J, Wang HT, Ong EH, Kusumawidjaja G, Phua JH, Tan TW, Soong YL, Fong KW, Soo KC, Wee JT, Zhu X-D, Boldrini L, Sun Y, **Chua ML**. Comparison of Radiomics Tools for Image Analyses and Clinical Prediction in Nasopharynx Cancer. *Br J Radiol* 2019; 92(1102): 20190271. (IF 2.196)
155. Zhang Z, Jayakumar M, Zheng X, Shikha S, Zhang Y, Bansal A, Poon DJ, Chu PL, Yeo EL, **Chua ML**, et al. **Upconversion superballs for programmable photoactivation of therapeutics. *Nat Commun* 2019; 10(1): 4586. (IF 12.121)**
156. Tan MH, Wee JT, **Chua ML**. The hunt for the perfect biomarker in nasopharyngeal carcinoma – the *RRAS* “race” beyond Epstein-barr virus? *Transl Cancer Res* 2019; 8(5): 1659-62. (IF 1.241)
157. Lv JW, Chen YP, Zhou GQ, Qi ZY, Tan LK, Lin L, Chen FP, Zhang LL, Huang XD, Liu RQ, Xu SS, Chen Y, Lin AH, Ma J, **Chua ML (Co-senior)**, Sun Y. **Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharynx cancer. *Nat Commun* 2019; 10(1): 3941. (IF 12.121)**
158. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen Y-P, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li GJ, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Liu N, Li

- YQ, **Chua ML (Co-senior)**, et al. **Gemcitabine and cisplatin induction chemotherapy nasopharyngeal carcinoma. N Engl J Med 2019; 381(12): 1124-35. (IF 74.699)**
159. Houlahan K, Shiah Y-J, Yao C, Huang V, Fraser M, Heisler LE, Livingstone J, Yamaguchi T, Rouette A, Foucal A, Espiritu SM, Sinha A, Sam M, Timms L, Johns J, Wong A, Meng A, Kron K, Murison A, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Lupien M, Fradet Y, Tetu B, McPherson JD, Kislinger T, **Chua ML**, et al. **Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nat Med 2019; 25(10): 1615-26. (IF 36.130)**
160. Chu PL, Shihabudeen WA, Low KP, Poon DJ, Ramaswamy B, Liang Z-G, Nei WL, Chua KL, Thong PS, Soo KC, Yeo EL, **Chua ML**. Vandetanib sensitises head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. *Photodiagnosis Photodyn Ther* 2019; 27: 367-74. (IF 2.894)
161. Lim SB, **Chua ML**, et al. Pan-cancer analysis connects tumor matrisome to immune response. *NPJ Precis Oncol* 2019; 3: 15. (IF 7.717)
162. **Chua ML**, Chua KL, Wee JT. Coming of age of bevacizumab in the management of radiation-induced cerebral necrosis. *Ann Transl Med* 2019; 7(7): 155. (IF 3.297)
163. Anderson CM, Kimple R, Lin A, Margalit D, **Chua ML**. De-escalation strategies in HPV-associated oropharynx cancer - Are we putting the Cart before the Horse? *Int J Radiat Oncol Biol Phys* 2019; 104(4): 705-9. (IF 5.859)
164. **Chua ML**. Circulating tumor DNA to personalize treatment in nasopharynx cancer – time to look “ahead”? *Int J Radiat Oncol Biol Phys* 2019; 104(2): 362-4. (IF 5.859)
165. **Chua ML**. Editorial comment on Berlin et al. International multicenter validation of an intermediate risk subclassification of prostate cancer managed with radical treatment without hormone therapy. *J Urol* 2019; 201(2): 291. (IF 5.925)
166. Zhao C, Miao JJ, Shen GZ, Li JG, Shi M, Zhang N, Hu GQ, Chen XZ, Hu XF, Wu SX, Chen JX, Shao XF, Wang L, Han F, Mai HQ, **Chua ML (Co-senior)**, Xie CH. **Anti-epidermal growth factor receptor monoclonal antibody combined with cisplatin and 5-Fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, Phase II clinical trial. Ann Oncol 2019; 30(4): 637-43. (IF 18.274)**
167. Iyer NG, **Chua ML**. **Multidisciplinary team meetings – challenges of implementation science. Nat Rev Clin Oncol 2019; 16(4): 205-6. (IF 53.276)**
168. Tan JS, Goh C, Koh YS, Li YQ, Tuan J, Chua ET, Tan TW, Wang ML, Lee LS, Tay KJ, Kanesvaran R, Toh CK, Tong AK, Lam W WC, **Chua ML**. ⁶⁸Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision making tool in Asian prostate cancer patients following prostatectomy. *Cancer Biol Med* 2019; 16(1): 157-66. (IF 5.432)
169. Lin L, Dou Q, Jin Y-M, Zhou G-Q, Tang Y-Q, Chen W-L, Su B-A, Liu F, Tao C-J, Jiang N, Li J-Y, Tang L-L, Xie C-M, Huang SM, Heng PA, Ma J, Wee JT, **Chua ML (Co-senior)**, et al. **Artificial Intelligence Automation for Head and Neck Radiotherapy Planning in Nasopharynx Cancer. Radiology 2019; 291(3): 677-86. (IF 7.931)**
170. Chen Y-P, Wang Y-Q, Lu J-W, Li Y-Q, **Chua ML**, et al. **Identification and Validation of Novel Microenvironment-based Immune Molecular Subgroups of Head and Neck Squamous Cell Carcinoma: Implications for Immunotherapy. Ann Oncol 2019; 30(1): 68-75. (IF 18.274)**
171. Liang Z-G, Kusumawidjaja G, Kazmi F, Wee JT, **Chua ML**. Intensity-modulated radiotherapy for paranasal sinuses and base of skull tumors. *Oral Oncol* 2018; 86: 61-8. (IF 3.979)

172. Berlin A, Murgic J, Hosni A, Pintilie M, Salcedo A, Fraser M, Kamel-Reid S, Zhang JB, Wang QQ, Ch'ng C, Deheshi S, Davicioni E, van der Kwast T, Boutros PC, Bristow RG, **Chua ML**. **Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy.** *Int J Radiat Oncol Biol Phys* 2019; **103(1): 84-91. (IF 5.859)**
173. Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Yousif F, Zhang YZ, Donmez N, Ahmed M, Guo HY, Volik S, Lapuk A, Petricca J, **Chua ML**, et al. **Widespread and Functional RNA Circularization in Localized Prostate Cancer.** *Cell* 2019; **176(4): 831-43. (IF 38.637)**
174. Bhandari V, Hoey C, Liu L, Lalonde E, Ray J, Livingstone J, Lesurf R, Shiah YJ, Vujcic T, Huang XY, Espiritu S, Heisler L, Yousif F, Huang V, Yamaguchi T, Yao C, Sabelnykova V, Fraser M, **Chua ML**, et al. **Molecular landmarks of tumor hypoxia across cancer types.** *Nat Genet* 2019; **51(2): 308-18. (IF 27.603)**
175. Chua KL, Shihabudeen WA, Shwe MT, Tan SH, Ong EH, Li XT, Lam PY, Soo KC, Soong YL, Fong KW, Tan TW, Wee JT, **Chua ML**. Intra- and Inter-patient Heterogeneity of DNA Damage Response Biomarkers in Nasopharynx Cancer: Post-hoc Analysis of a Randomised Controlled Trial. *BMC Cancer* 2018; **18(1): 1095. (IF 3.150)**
176. Yeo EL, Li YQ, Soo KC, Wee JT, **Chua ML**. Combinatorial Strategies of Radiotherapy and Immunotherapy in Nasopharyngeal Carcinoma. *Chin Clin Oncol.* 2018; **7(2):15. (IF 2.8)**
177. Bissey PA, Law J, Bruce J, Shi W, Aline R, **Chua ML**, et al. Dysregulation of the MiR-449b Target TGFBI Alters the TGF β Pathway to Induce Cisplatin Resistance in Nasopharyngeal Carcinoma. *Oncogenesis* 2018; **7(5): 40. (IF 6.119)**
178. Liu X, Zhang Y, Tang LL, Le QT, **Chua ML**, et al. **The 10-year Landscape of Radiotherapy vs Non-Radiotherapy Oncology Clinical Trials in ClinicalTrials.gov.** *JAMA Oncol* 2018; **4(8): 1073-9. (IF 31.777)**
179. Li YQ, Tan SJ, Wee JT, **Chua ML**. Adaptive Radiotherapy in the Treatment of Head and Neck Cancers: Fact or Fallacy to Improve Therapeutic Ratio? *Cancer Radiother* 2018; **22(3): 287-95. (IF 1.014)**
180. Poh SS, **Chua ML**, Wee TJ. Why we should give spatially fractionated radiation therapy (GRID) a second look—especially in nasopharyngeal carcinoma. *Ann Nasopharynx Cancer* 2018; **2: 4.**
181. Li YQ, Chua KL, Chua ET, **Chua ML**. “Cor Occidere”: A Novel Strategy of Targeting the Tumor Core by Radiosurgery in a Radio- and Chemo-resistant Intracranial Hemangiopericytoma. *Chin Clin Oncol* 2018; **7(1): 10. (IF 2.8)**
182. Li YQ, Tian YM, Tan SH, Kusumawidjaja G, Zhao C, Tan TW, Fong KW, Sommat K, Soong YL, Wee JT, Fei H, **Chua ML**. **A Prognostic Model for Stratification of Radioresistant Nasopharynx Cancer to Curative Salvage Radiotherapy.** *J Clin Oncol* 2018; **36(9): 891-9. (IF 44.544)**
183. Espiritu SM, Liu L, Rubanova Y, Bhandari V, Holgersen E, Szyca L, Fox N, **Chua ML**, et al. **The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression.** *Cell* 2018; **173(4): 1003-13. (IF 38.637)**
184. Li YQ, Khin NS, **Chua ML**. The Evolution of EBV Detection in Nasopharynx Cancer. *Cancer Bio Med* 2018; **15(1): 1-5. (IF 5.432)**
185. Berlin A, Ardalan A, **Chua ML**, et al. Curative Radiotherapy at Time of Progression under Active Surveillance Compared with Upfront Radical Radiotherapy for Prostate Cancer. *Int J Radiat Oncol Biol Phys* 2018; **100(3): 702-9. (IF 7.04)**
186. Guan SP, Lam AT, Newman JP, Chua KL, Kok CY, Chong ST, **Chua ML**, Lam PY. Matrix metalloproteinase-1 facilitates MSCs migration via its proteinase activities on IGF-2/IGFBP2 complex. *FEBS Open Bio* 2017; **8(1): 15-26. (IF 2.231)**

187. Miller JA, Guillozet-Bongaarts A, Gibbons LE, Postupna N, Renz A, Beller AE, Sunkin SM, Ng L, Rose SE, Smith KA, Szafer A, Barber C, Bertagnolli D, Bickley K, Brouner K, Caldejon S, Chapin M, **Chua ML**, et al. Neuropathological and transcriptomic characteristics of the aged brain. *Elife* 2017; 6: e31126. (IF 7.08)
188. Chua KL, Tan DB, **Chua ML**, Lo S. The Promise of Stereotactic Body Radiotherapy – Next Phase of Integration into Oncological Practice. *Chin Clin Oncol* 2017; 6(Suppl 2): S8. (IF 2.8)
189. Chua KL, Sim I, Fong KW, **Chua ML**, Onishi H. Stereotactic Body Radiotherapy in Localised Lung Cancer. *Chin Clin Oncol* 2017; 6(Suppl 2): S20. (IF 2.8)
190. Tan SJ, Li X-T, Ahamed SW, Chua KL, Lam PY, Soo KC, **Chua ML**. Exploiting Molecular Genomics in Precision Radiation Oncology: A Marriage of Biological and Physical Precision. *Chin Clin Oncol* 2017; 6(Suppl 2): S19. (IF 2.8)
191. Hopkins JF, Sabelnykova V, Weischenfeldt J, Simon R, Aguiar JA, Alkallas R, Heisler LE, Zhang J, Watson JD, **Chua ML**, et al. **Mitochondrial mutations drive prostate cancer aggression. Nat Comms 2017; 8(1): 656. (IF 12.121)**
192. Mahamud O, So J, **Chua ML (Co-first)**, Bristow RG. Targeting DNA repair for precision radiotherapy – Balancing the therapeutic ratio. *Curr Probl Cancer* 2017; 41(4): 265-72. (IF 3.264)
193. **Chua ML**, Lo W, Pintilie M, et al. **A Prostate Cancer “Nimbusus”: Genomic instability and SchLAP1 dysregulation underpins aggression of intraductal and cribriform sub-pathologies. Eur Urol 2017; 72(5): 665-74. (IF 17.947; Accorded Platinum Priority and Cover Page of Issue)**
194. Raziee H, Moraes FY, Murgic J, **Chua ML**, et al. Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. *Radiother Oncol* 2017; 123(3): 459-65. (IF 6.28)
195. **Chua ML**, van der Kwast TH, Bristow RG. **Intraductal carcinoma of the prostate gland: Anonymous to Ominous. Eur Urol 2017; 72(4): 496-8. (IF 17.947)**
196. Fraser M, Sabelnykova V, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin XH, Masella AP, Fox N, Xie M, Prokopec SD, Berlin A, Lalonde E, Trudel D, Luo XM, Beck TA, Meng A, Zhang JY, D’Costa A, Denroche RE, Kong HY, Espiritu SM, **Chua ML**, et al. **Genomic hallmarks of localized, non-indolent prostate cancer. Nature 2017; 541(7637): 359-64. (IF 42.778)**
197. Lalonde E, Alkallas R, **Chua ML**, et al. **Translating a prognostic DNA genomic classifier into the clinic: retrospective validation in 563 localized prostate tumours. Eur Urol 2017; 72(1): 22-31. (IF 17.947; Accorded Platinum Priority)**
198. Chua KL, Kusumawidjaja G, Murgic J, **Chua ML**. Adjuvant Treatment following Radical Cystectomy for Muscle-invasive Urothelial Carcinoma and Variant Histological Subtypes – Is There a Role for Radiotherapy? *ESMO Open* 2016; 1(6): 000123. (IF 5.329)
199. **Chua ML**, Chan AT. **Gemcitabine: a game changer in nasopharyngeal carcinoma. Lancet 2016; 388(10054): 1853-54. (IF 60.392)**
200. **Chua ML**, et al. Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Locally Advanced Nasopharyngeal Carcinoma: a Pooled Analysis of Two Randomized Controlled Trials. *Eur J Cancer* 2016; 67: 119-29. (IF 7.275)
201. **Chua ML**, Bristow RG. **Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or ‘Frenemy’? Clin Cancer Res 2016; 22(13): 3124-6. (IF 10.107)**
202. Wee JT, Soong YL, **Chua ML**. Nasopharyngeal carcinoma—past lessons and a glimpse into the future. *Chin Clin Oncol* 2016; 5(2): 14. (IF 2.8)

203. Wee JT, Soong YL, Poh SS, **Chua ML**. Nasopharyngeal carcinoma – closing remarks. *Chin Clin Oncol* 2016; 5(2): 29. (IF 2.8)
204. Somaiah N, **Chua ML (Co-first)**, et al. Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy. *Radiother Oncol* 2016; 119(2): 244-9. (IF 6.28)
205. Nuta O, Somaiah N, Boyle S, **Chua ML**, et al. Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy. *Cancer Lett* 2016; 374: 324-30. (IF 7.360)
206. Kusumawidjaja G, Gan P, Ong WS, Teyateeti A, Dankulchai P, Tan DYH, Chua ET, Chua KL, Tham CK, Wong FY, **Chua ML**. Dose-escalated Intensity-modulated Radiotherapy and Irradiation of Subventricular Zones in Relation to Tumor Control Outcomes of Patients with Glioblastoma Multiforme. *Onco Targets Ther* 2016; 9: 1115-22. (IF 4.345)
207. Poh SS, **Chua ML**, Wee J. Carcinogenesis of Nasopharyngeal Carcinoma - An Alternative Hypothetic Mechanism. *Chin J Cancer* 2016; 35(1): 9. (IF 5.760)
208. **Chua ML**, Wee J, Hui EP, Chan AT. **Nasopharyngeal carcinoma. *Lancet* 2016;387(10022): 1012-24. (IF 60.392)**
209. **Chua ML**, et al. DNA double-strand break repair and induction of apoptosis in *ex vivo* irradiated blood lymphocytes in relation to late normal tissue effects following breast radiotherapy. *Radiat Environ Biophys* 2014; 53(2): 355-64. (IF 1.321)
210. **Chua ML**, Rothkamm K. Biomarkers of radiation exposure: Can they predict normal tissue radiosensitivity? *Clin Oncol* 2013; 25(10): 610-6. (IF 3.113)
211. Lim TC, **Chua ML (Co-first)**, et al. Comparison of MRI, CT and ¹⁸F-FDG-PET/CT for the detection of intracranial disease extension in nasopharyngeal carcinoma. *Head Neck Oncol* 2012; 4(2): 49.
212. **Chua ML**, et al. **In-vitro interaction of cyclooxygenase-2 (COX-2) inhibitors with radiation in nasopharyngeal carcinoma: dependent on sequence of administration. *Austral-Asian J of Cancer* 2012; 11(1): 27-31. (Published in conjunction with ‘Eminent Scientist of the Year 2011’ award)**
213. **Chua ML**, et al. Residual DNA and chromosomal damage in *ex vivo* irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. *Radiother Oncol* 2011; 99(3): 362-6. (IF 6.28)
214. **Chua ML**, et al. Inter-individual and inter-cell type variation in residual DNA damage after *in vivo* irradiation of human skin. *Radiother Oncol* 2011; 99(2): 225-30. (IF 6.28)
215. Loong SL, Siok GHJ, Li HH, Wee TSJ, Yap SP, **Chua ML**, et al. Negligible or weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01). *Radiat Oncol* 2009; 4(1): 23. (IF 2.817)
216. **Chua ML**, et al. Comparison of four different modalities for distant metastases staging in Endemic Nasopharyngeal Carcinoma. *Head Neck* 2009; 31(3): 346-54. (IF 2.538)

Invited Book Chapters

1. **Chua ML**, Matt Lechner, Brigitte Ma. **Chapter 14: Nasopharynx Cancer. In: *The 12th edition of Cancer: Principles & Practice of Oncology*. *Most widely used oncology textbook globally [In press, Jan 2023]**
2. Tng DJ, Chong LM, **Chua ML**, Zhong Y, Yong KT. Chapter 2: Nanoparticles for enhanced radiotherapy and imaging applications. In: *Nanomaterials for Cancer Detection Using Imaging Techniques and Their Clinical Applications*, Springer Cham. DOI:10.1007/978-3-031-09636-5. [In press, Oct, 2022]

3. Bacorro W, Mejia M, Van Limbergen E, Wee JT, **Chua ML**. Chapter 14: Nasopharynx Cancer. In: The GEC ESTRO: Handbook of Brachytherapy. [*In press, Oct 2019*]
4. **Chua ML**, Murgic JM, Teh BS. Chapter 11: Radiotherapy in the Management of Prostate Cancer. In: Medical Radiology, Springer Berlin Heidelberg. DOI:10.1007/174_2017_11. [*In press, Feb 2017*]
5. Huang SH, **Chua ML**, Caparrotti F, O'Sullivan B. Chapter 10: Treatment of viral-associated head and neck cancer (oropharyngeal and nasopharyngeal cancer). In: Vermorken J, O'Sullivan B, Leemans R, Budach V, Nicolai P, and Machiels JP, eds. Critical issues in Head and Neck Oncology – Key concepts from the Fifth THNO Meeting. [*In press, Sep 2016*]

Peer-reviewed Abstracts (First / Senior Author; highlighted presentations in bold)

1. **Chua ML**, et al. RIBBON-UM: tReatment Individualisation By EBV stratificatiOn in Nasopharyngeal carcinoma (NPC): a phase 2, multi-arm UMBrella platform trial. Poster Presenter, ASCO Annual Meeting 2025, Chicago.
2. Hong BH, Tay KJ, Ong EH, Tan KM, Tan YG, Law YM, Ngo NT, Tan PH, Yuen JS, Ho HS, Chen K, Peng JP, Sam XX, Tuan JK, Kanavarar R, Gupta RT, Rozen S, Polascik TJ, Liu Y, Proudfoot J, Davicioni E, Khor LY, **Chua ML**. **High Genomic Risk Associated with Clinically Significant Prostate Cancer (csPCa) Failures following Focal Therapy (FT)**. Poster Presenter, ESMO Asia Congress 2024, Singapore. *Best Poster award for fellow (Mr Hong BH)
3. **Chua ML**, et al. **Accuracy of Plasma Epstein-Barr virus (EBV) DNA for Disease Surveillance in Endemic Nasopharyngeal Carcinoma (NPC): Analysis of a Real-world Database (RWD)**. Oral Presenter, ESMO Asia Congress 2024, Singapore
4. Tan EM, Beh CY, Yeo C, Hong BH, Poon DJ, Chu JP, Susanti D, Tai PL, Yeo EL, **Chua ML**. **Molecular Profiling of Radioresistant (RR) Head and Neck (HNC) and Prostate Cancers (PCa) Implicates Heterochromatin Remodeling as a Mechanism of Radiotherapy (RT) Resistance**. Poster presenter, ASCO Breakthrough 2024, Yokohama *Conquer Foundation Merit award for fellow (Ms Tan E)
5. Zhang X, Yan J, Lei QQ, Zhang L, Yang JY, Wang F, Wang YW, Tan SH, **Chua ML, et al.** **A Randomized, Multicenter, Phase II Trial of Camrelizumab (Cam) With and Without Metastasis-directed Therapy (MDT) in Recurrent/Metastatic Nasopharyngeal Carcinoma (R/M-NPC)**. Poster presenter, ASCO Breakthrough 2024, Yokohama *Conquer Foundation Merit award for fellow (Ms Zhang X)
6. **Chua ML**, et al. Tumor-Immune Microenvironment (TIME) Delineates Disparate Ascending (A) and Descending (D) Subtypes of Nasopharyngeal Carcinoma (NPC). Poster presenter, ASCO Breakthrough 2024, Yokohama.
7. Tan JS, Neo JL, Yip PL, Ong EH, Chow WM, Wee JT, Fong KW, Soong YL, Tan TW, Tan JS, Sin SY, Tan DT, Ang MK, Tan SH, Lim DT, **Chua ML; Singapore NPC LCG Consortium**. **Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)**. ESMO Congress 2023, Madrid *ESMO Merit award for resident (Dr Tan JS)
8. Yeo EL, Ong E, Neo JL, Chow WM, Tan KM, Tan JS, Yeong JP, Lim TK, Hwang JS, Ng QS, Soong YL, Ang MK, Tan SH, **Chua ML**. **Association of Claudin-1 overexpression with immune exclusion in nasopharyngeal carcinoma and its potential as a novel therapeutic target**. Poster presenter, ASCO Breakthrough 2023, Yokohama *Conquer Foundation research award for fellow (Dr Yeo EL)
9. Hong BH, Hakansson AK, Ong E, Chow WM, Tay K-J, Tuan JK, Wang ML, Lee LS, Kanavarar R, Liu Y, Davicioni E, Khor LY, **Chua ML**. **DNA damage response (DDR) variants and effects on the tumour transcriptome and microenvironment in East Asian Prostate Cancers**. Poster presenter, ASCO Breakthrough 2023, Yokohama *Conquer Foundation research award for fellow (Mr Hong BH)

10. Lui RN, Billod J, Frentzas S, Hoang H, Eaton V, Lei JX, Garrett-Mayer E, Goldstein D, Dent R, **Chua ML**. **An ASCO Leadership Development Project to Understand Barriers to Clinical Cancer Research in the Asia-Pacific. Oral presenter, ASCO Breakthrough 2023, Yokohama *Conquer Foundation research award for fellow (Dr Lui RN)**
11. Lua JY, Chua JW, Ong EH, Chow M, Tay KJ, Tuan J, Wang ML, Lee LS, Kanesvaran R, Khor LY, **Chua ML**. Germline DNA Damage Response (DDR) Mutations in East Asian (EA) Prostate Cancer (PCa). Poster presenter, ASCO Genitourinary Cancers Symposium 2023, San Francisco
12. Neo JL, Ong EH, Sim AY, Miao JJ, Wee JT, Fong KW, Soong YL, Tan TW, Tan JS, Sin SY, Tan DT, Ang MK, Tan SH, Lim DT, **Chua ML**. **Characterization of Minimal Residual Disease (MRD) post-Radiotherapy (RT) in Nasopharyngeal Carcinoma (NPC) Identifies a Favourable Subgroup with Low Risk of Relapse. Mini-oral presenter, ESMO Asia Congress 2022, Singapore**
13. Chan SP, Chow E, **Chua ML**. **A quadratic phenotypic optimization drug screening platform (QPOP) identified chromatin modification as a potential strategy to target radioresistant (RR) head and neck cancers (HNC). Oral presenter, ASTRO Annual Meeting 2022, San Antonio**
14. Yeo C, Yeo EL, Poon DJ, Susanti D, Chu PL, Sim AY, **Chua ML**. **Genomic and Transcriptomic Profiling of Radioresistant (RR) Cancer Models Revealed Hallmarks of Tumor Aggression. Oral presenter, ASTRO Annual Meeting 2022, San Antonio**
15. **Chua ML**, et al. Comparative transcriptomic analyses of 100,691 primary tumours from East Asian and North American men with prostate cancer. Poster presenter, ESMO Congress 2022, Paris
16. Tan HQ, Cai JH, Sim AY, Huang L, **Chua ML**. Voxel-based radiomics outlines spatial heterogeneity of cerebral radiation necrosis (RN) associated with bevacizumab (Bev) response in head and neck radiotherapy (RT) patients. Poster presenter, ASCO Annual Meeting 2022, Chicago
17. Ong EH, Sim AY, Susanti D, Tan TW, Fong KW, Soong YL, Wee JT, Lim DW, Iyer NG, Abazeed M, Bei JX, **Chua ML**. **Germline risk variants associated with poorer disease prognosis in nasopharyngeal carcinoma. Poster presenter, Gordon Research Conference Nasopharyngeal Carcinoma 2022, Barcelona**
18. Sim AY, Ong EH, Huang L, Low KP, Susanti D, Tan TW, Fong KW, Soong YL, Tan GS, Lim TK, Wee JT, Lim DW, Iyer NG, Hwang JS, Bei JX, Abazeed M, **Chua ML**. **A genomic classifier designed by semi-supervised clustering prognosticates for survival in endemic nasopharyngeal carcinoma. Poster presenter, Gordon Research Conference Nasopharyngeal Carcinoma 2022, Barcelona**
19. Sim AY, Hakansson A, Ong EH, Lau AS, Low KP, Wong TR, Tan N, Tan JS, Tuan JK, Tan TW, Wang ML, Tay KJ, Yeong JS, Lee LS, Kanesvaran R, Tan MC, Liu Y, Davicioni E, Khor LY, **Chua ML**. Comparative genomic analyses between Asian and Caucasian prostate cancers in an 80,829 patient cohort. Poster presenter, ASCO Genitourinary Cancers Symposium 2022, San Francisco
20. **Chua ML**, et al. An immune-based genomic classifier (GC) prognosticates for survival in endemic nasopharyngeal carcinoma. Poster presenter, ASTRO Annual Meeting 2021 (Virtual)
21. Miao JJ, Lin WG, Tan SH, Li JG, Yi JL, Zhang Y, Gong XC, Xiang YQ, Chen QY, Chen MY, Lv Xing, Xia WX, Tang LQ, Deng XW, Guo X, Mai HQ, Han F, **Chua ML**, et al. **Adjuvant Capecitabine in Locoregionally Advanced Nasopharyngeal Carcinoma: A Multicenter Randomized Controlled Phase III Trial. Oral presenter, ASCO Annual Meeting 2021 (Virtual) *Philip Francis Mulvey III Endowed Conquer Foundation Merit Award for best submitted head and neck cancer abstract**
22. Chu PL, Yeo EL, Poon DJ, Chen CB, Ren MQ, Vajandar S, Susanti D, Tan HQ, Park SY, Osipowicz T, Liu SK, Soo KC, **Chua ML**. Proton irradiation sensitises cancer cell lines with acquired radioresistance by exploiting differentially dysregulated DNA damage response pathways. Poster presenter, AACR Annual Meeting 2021 (Virtual)

23. Sim YA, Ong EH, Huang L, Low KP, Susanti D, Tan TW, Fong KW, Soong YL, Tan GS, Lim TK, Wee JT, Lim DW, Iyer NG, Hwang JS, Abazeed M, Bei JX, Chua ML. Germline variants associated with poorer disease prognosis in nasopharyngeal carcinoma. Poster presenter, AACR Annual Meeting 2021 (Virtual)
24. Yeo EL, **Chua ML**. Molecular signatures of radioresistance in cancer cell lines. Poster presenter, AACR Radiation Science and Medicine 2021 (Virtual)
25. Yee SW, Woo WY, Sim AY, Low KP, Meng A, Tan JS, Tuan JK, Tan TW, Wang ML, Tay K-J, Cheng CW, Yeong JP, Liu Y, Lee LS, Kanesveran R, Tan MC, Davicioni E, Khor LY, **Chua ML**. Investigation of a 22-gene genomic classifier for risk stratification & molecular subtyping in an Asian prostate cancer cohort. Poster presenter, ASCO Genitourinary Cancers Symposium 2021 (Virtual)
26. Woo WY, Yee SW, Sim AY, Low KP, Meng A, Tan JS, Tuan JK, Tan TW, Wang ML, Tay K-J, Cheng CW, Yeong JP, Lee LS, Kanesveran R, Tan MC, Davicioni E, Liu SY, Khor LY, **Chua ML**. **Comparison of a 22-gene genomic classifier (GC) with NCCN for risk stratification of Asian prostate cancers. Mini-oral presenter, ESMO Asia Congress 2020, Singapore**
27. Ong EH, Sim AY, Huang L, Low KP, Woo WY, Susanti D, Wang HT, Tan TW, Fong KW, Soong YL, Tan GS, Lim TK, Wee JT, Lim DW, Iyer GN, Hwang JS, Abazeed M, Bei JX, **Chua ML**. **Distinct phenotypes of locoregionally advanced nasopharyngeal carcinoma (LA-NPC) harbor disparate survival outcomes and are associated with germline mutations. Oral proffered presenter, ESMO Asia Congress 2020, Singapore**
28. Tan MT, Woo WY, Sim AY, Tuan JT, Tan TW, Wang ML, Chua ET, Ong EH, Kanesvaran R, Tay KJ, Lee LS, Khor LY, Poh JS, Tan CS, **Chua ML**. Combinatorial abiraterone acetate/enzalutamide and radical radiotherapy in node-positive prostate cancer. Poster presenter, ASCO Genitourinary Cancers Symposium 2020, San Francisco
29. Miao JJ, Di MP, Chen BY, Wang L, Cao YQ, Xiao WW, Wong KH, Luo H, Zhu MY, Huang HG, Huang SM, Han F, Deng XW, Xiang YQ, Lv X, Xia WX, Tan SH, Wee JT, Guo X, **Chua ML**. **A Prospective 10-year Observational Study of Reduction of Radiotherapy Clinical Target Volume and Dose in Early-stage Nasopharyngeal Carcinoma. Mini-oral presenter, ESMO Asia Congress 2019, Singapore *Merit award recipient for fellow (Dr Miao JJ)**
30. A Chimmiri, HT Wang, A Yeo, WY Woo, MC Tan, LY Khor, J Tuan, TW Tan, ML Wang, WS Looi, **Chua ML**. **A novel computational OMICS and non-OMICS approach for identifying true pathogenic risk variants for Asian prostate cancer. Mini-oral presenter, ASCO Breakthrough 2019, Bangkok *Conquer Foundation research award for fellow (Ms Chimmiri A)**
31. HT Wang, EL Yeo, J Hwang, GS Tan, EH Ong, KP Low, A Chimmiri, WY Woo, WL Nei, TK Lim, MC Tan, J Loh, C Teo, H Heah, G Tay, JT Wee, NG Iyer, Y Sun, JX Bei, **Chua ML**. **Immune dysregulation underpins radioresistance in nasopharyngeal carcinoma. Poster presenter, ASCO Breakthrough 2019, Bangkok *Conquer Foundation research award for fellow (Dr Wang HT)**
32. Mark HL Tan, Liang Z-G, Zhang F, Tan LK, Lin L, Lenkowicz J, Wang HT, Ong EH, Kusumawidjaja G, Phua JH, Tan TW, Soong YL, Fong KW, Soo KC, Wee JT, Zhu X-D, Boldrini L, Sun Y, **Chua ML**. Radio-transcriptomic phenotypes predict radioresistance in nasopharyngeal carcinoma. Poster presenter, ASTRO Annual Meeting 2019, Chicago
33. Miao JJ, Wang L, Hu CS, Lin SJ, Tan SH, Ong E, Chen XZ, Chen YY, Zhong YH, Jin F, Lin Q, Lin SM, Hu XF, Zhang N, Wang RS, Wang C, Shi HP, **Chua ML**. **A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by induction chemotherapy and chemoradiotherapy. Oral presenter, ASTRO Annual Meeting 2019, Chicago**
34. **Chua ML**, Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen Y-P, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li GJ, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY,

- Liu N, Li YQ, Sun Y, Ma J. **Gemcitabine and cisplatin induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicenter, randomized controlled trial. Oral presenter, *Selected for Best of ASCO Series 2019, Singapore**
35. Ma J, Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen Y-P, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li GJ, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Liu N, Li YQ, **Chua ML**. **Gemcitabine and cisplatin induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicenter, randomized controlled trial. Oral presenter, ASCO Annual Meeting 2019, Chicago**
 36. Lv JW, Chen YP, Zhou GQ, Qi ZY, Tan LK, Lin L, Chen FP, Zhang LL, Huang XD, Liu RQ, Xu SS, Chen Y, Lin AH, Ma J, **Chua ML**. **Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharynx cancer. Poster discussion, ASCO Annual Meeting 2019, Chicago *Conquer Cancer Foundation ASCO Merit Award Winner for fellow (Dr Lv JW)**
 37. Miao JJ, Wang L, Hu CS, Lin SJ, Tan SH, Ong E, Chen XZ, Chen YY, Zhong YH, Jin F, Lin Q, Lin SM, Hu XF, Zhang N, Wang RS, Wang C, Shi HP, **Chua ML**. **A Multicenter Prospective Observational Study of Nutritional Status on Survival in Locally Advanced Nasopharynx Cancer Treated by Induction Chemotherapy and Chemoradiotherapy. Poster presenter, ASCO Annual Meeting 2019, Chicago *Conquer Cancer Foundation ASCO Merit Award Winner for fellow (Dr Miao JJ)**
 38. Chen FP, Zhou GQ, Luo YS, Tan LK, Tan SH, Zheng Y, Lin L, Lv J-W, Kou J, Huang X-D, Zheng Z-Q, He X-J, Wu C-F, Zhang L-L, Zhu B-T, He X-Y, Ma J, Guo Y, **Chua ML**. **Development of a Clinicomolecular Risk Stratification System for Non-metastatic Nasopharyngeal Carcinoma using Epstein–Barr virus DNA and TNM Stage in 9,160 endemic cases from Southern China. Poster presenter, ASCO Annual Meeting 2019, Chicago *Conquer Cancer Foundation ASCO Merit Award Winner for fellow (Dr Chen FP)**
 39. Chua KL, Fehlings M, Nardin A, Chu PL, Yeo EL, Lin X-T, Ong EH, Woo WY, Low KP, Poon D, Chin F, Nei WL, Farid M, Kanavarar R, Dent R, Wee J, Iyer GN, Tan DS, Soo KC, Newell E, **Chua ML**. High dimensional immune profiling reveals synergism between ablative radiotherapy and immune checkpoint blockade in the treatment of human cancers. Poster presenter, AACR Annual Meeting 2019, Atlanta
 40. Sin SH, **Chua ML**. Comparison of soft tissue and bone-based matching for accuracy of volumetric modulated radiation therapy (VMAT) in laryngeal and hypopharyngeal cancers. Poster presenting, Australian Society of Medical Imaging and Radiation Therapy's 14th National Conference 2019, Adelaide
 41. Chua KL, Fehlings M, Nardin A, Chu PL, Yeo EL, Lin X-T, Ong EH, Woo WY, Low KP, Poon D, Chin F, Nei WL, Farid M, Kanavarar R, Dent R, Wee J, Iyer GN, Tan DS, Soo KC, Newell E, **Chua ML**. The role of high dimensional immune profiling in understanding responses to ablative radiotherapy and immune checkpoint blockade. Poster presenter, ASCO-SITC Immuno-oncology Symposium 2019, San Francisco
 42. Tan JS, Tan SX, Li YQ, Woo WY, Wang HT, Low KP, Tan AC, Tuan JK, Tan TW, Wang ML, Tay KJ, Lee LS, Tan DY, Teh JT, **Chua ML**. Clinical and genetic determinants of toxicity and quality of life (QOL) outcomes for SBRT in Asian Prostate Cancer (PROSTAR). Poster presenter, ASCO Genitourinary Cancers Symposium 2019, San Francisco
 43. Kusumawidjaja G, Li YQ, Gan SA, Phua JH, Ng YY, **Chua ML**. A Radiomics Signature for Treatment Stratification in Advanced and Recurrent Nasopharynx Cancer. Poster presenter, ASTRO Annual Meeting 2018, San Antonio
 44. Li YQ, Tian YM, Tan SH, Kusumawidjaja G, Zhao C, Tan TW, Fong KW, Sommat K, Soong YL, Wee JT, Fei H, **Chua ML**. A Prognostic Model for Stratification of Radioresistant Nasopharynx Cancer to Curative Salvage Radiotherapy. Poster presenter, ASTRO Annual Meeting 2018, San Antonio

45. Berlin A, Murgic J, Hosni A, Pintilie M, Salcedo A, Fraser M, Kamel-Reid S, Zhang JB, Wang QQ, Ch'ng C, Deheshi S, Davicioni E, van der Kwast T, Boutros PC, Bristow RG, **Chua ML**. **A Biopsy-based Genomic Classifier Predicts Biochemical Failure and Metastasis after Definitive Radiation without Hormone Therapy in a Prospective Cohort of Intermediate-risk Prostate Cancer. Oral presenter, ASTRO Annual Meeting 2018, San Antonio**
46. Chua KL, Fehlings M, Nardin A, Chu PL, Yeo EL, Lin X-T, Ong EH, Woo WY, Low KP, Poon D, Chin F, Nei WL, Farid M, Kanesvaran R, Dent R, Wee J, Iyer GN, Tan DS, Soo KC, Newell E, **Chua ML**. **Dependency of combinatorial radio-immunotherapy responses on the systemic immune response. Oral presenter, ASTRO Annual Meeting 2018, San Antonio**
47. Chua KL, Lin XT, Yeo EL, Ahmad SW, Chu PL, Low KP, Poon DJ, Ong EH, Wee JT, Nardin A, Fehlings M, Newell E, Soo KC, **Chua ML**. **Dependency of radiotherapy and combinatorial radio-immunotherapy responses on the systemic T-cell immune response. Poster presenter, ASCO Annual Meeting 2018, Chicago. *Conquer Cancer Foundation ASCO Merit Award Winner for fellow (Dr Chua KL)**
48. Li YQ, Koh YS, Tuan JT, Chua ET, Tan TW, Wang ML, Teh JY, **Chua ML**. Patient-reported Quality-of-life Results of a Phase II Study of **PRO**state **ST**ereotactic **Ab**lative **Radio**therapy in Asian prostate cancers (**PROSTAR**). Poster presenter, ESTRO 37 Annual Meeting 2018, Barcelona
49. **Chua ML**, et al. A biopsy-based genomic classifier predicts biochemical failure after definitive radiation without hormone therapy in intermediate risk prostate cancer. Poster presenter, ASCO Genitourinary Cancers Symposium 2018, San Francisco
50. Tan JS, Goh C, Li YQ, Tuan J, Chua ET, Tan TW, Wang ML, Lee LS, Tay KJ, Lam W, **Chua ML**. ⁶⁸Ga Prostate-specific Membrane Antigen-PET as a diagnostic and clinical decision making tool in biochemical recurrences post-radical prostatectomy. Poster presenter, ASCO Genitourinary Cancers Symposium 2018, San Francisco
51. **Chua ML**, et al. **Genomic, epigenomic, and clonal architecture of radioresistant prostate cancer. Oral presenter, ASTRO Annual Meeting 2017, San Diego**
52. Chua KL, Ahamed SW, Shwe MT, Tan SH, Fong KW, Wee JT, Tan TW, Rothkamm K, **Chua ML**. **Lymphocyte apoptosis predicts for candidates for treatment de-intensification in endemic EBV-associated nasopharynx cancers. Oral presenter, ASTRO Annual Meeting 2017, San Diego**
53. Chua KL, Ahamed SW, Shwe MT, Tan SH, Fong KW, Wee JT, Tan TW, Rothkamm K, **Chua ML**. **Lymphocyte apoptosis predicts for candidates for treatment de-intensification in endemic EBV-associated nasopharynx cancers. Poster presenter, 15th Wolfsberg International Meeting 2017, Ermatingen**
54. **Chua ML**, et al. **Genomic architecture of radioresistant prostate cancer. Oral presenter (Top 3 proffered paper), 15th Wolfsberg International Meeting 2017, Ermatingen**
55. Chua KL, Ahamed SW, Shwe MT, Tan SH, Fong KW, Wee JT, Tan TW, Rothkamm K, **Chua ML**. DNA damage response biomarkers for clinical stratification to treatment de-intensification in EBV+ nasopharynx cancers. Poster presenter, AACR Annual Meeting 2017, DC
56. **Chua ML**, et al. Genomic architecture of radioresistant prostate cancer. Poster presenter, AACR Annual Meeting 2017, DC
57. **Chua ML**, et al. **Genomic architecture of radioresistant prostate cancer. Top abstract selected for ASCO Direct-sponsored interview (<http://www.medtalks.eu/asco-gu-2017-posters-a26-2/>); Poster presenter, ASCO Genitourinary Cancers Symposium 2017, Orlando**
58. **Chua ML**, et al. **Genomic architecture of prostate cancer at recurrence following radiotherapy. Oral presenter, ASTRO Annual Meeting 2016, Boston**

59. Ahamed SW, Chua KL, Shwe MT, Kwok LL, Hande P, Fong KW, Soong YL, Wee JT, Tan TW, Rothkamm K, **Chua ML**. Multimodal testing of DNA damage response markers for prediction of normal tissue toxicities following head and neck intensity-modulated radiotherapy. Poster presenter, ASTRO Annual Meeting 2016, Boston
60. Li YQ, Tan SH, Fong KW, Soong YL, Wee JT, Tan TW, **Chua ML**. Re-irradiation of Recurrent Nasopharyngeal Carcinoma. Poster presenter, ASTRO Annual Meeting 2016, Boston
61. **Chua ML**, et al. **Neutrophil-lymphocyte ratio as a prognostic marker in nasopharyngeal carcinoma – a pooled analysis of two randomised trials. Poster presenter, Gordon Research Conference Nasopharyngeal Carcinoma 2016, HK, SAR**
62. **Chua ML**, et al. Combinatorial genomics and pathological indices to stratify for unfavourable intermediate-risk prostate cancer. Poster presenter, ASCO Annual Meeting 2016, Chicago
63. **Chua ML**, et al. **Prognostic significance of copy number alteration burden in unfavourable intermediate-risk prostate cancers harbouring intraductal carcinoma and cribriform architecture. Oral presenter, Mini-symposium, AACR Annual Meeting 2016, New Orleans**
64. **Chua ML**, et al. Copy number alterations of DNA mismatch repair genes as novel prognostic markers in localised prostate cancer. Poster presenter, ASCO Genitourinary Cancers Symposium 2016, San Francisco
65. Murgic J*, **Chua ML***, et al. Intraductal carcinoma and cribriform architecture as novel prognostic factors in patients with prostate cancer treated with dose-escalated radiotherapy. *Co-first Poster presenters, ASCO GU Cancers Symposium 2016, San Francisco
66. **Chua ML**, et al. Plasma EBV DNA and Neutrophil-Lymphocyte Ratio as Predictive Markers for Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma. Poster presenter, European Cancer Congress 2015, Vienna
67. **Chua ML**, et al. **Plasma EBV DNA as a Predictive Biomarker in Patients with Endemic Nasopharyngeal Carcinoma Treated with Induction Chemotherapy and Concurrent Chemo-radiotherapy. Oral presenter, ASTRO 56th Annual Meeting 2014, San Francisco**
68. Kusumawidjaja G, Gan P, Ong WS, Dankulchai P, Teyateeti A, Tan DYH, Chua ET, Tham CK, Wong FY, **Chua ML**. Dose-escalated intensity modulated radiotherapy and increased radiation doses to subventricular zones in treatment outcomes of patients with glioblastoma multiforme. Poster presenter, ASTRO 56th Annual Meeting 2014, San Francisco
69. **Chua ML**, et al. Comparison of *in vivo* skin and *in vitro* blood lymphocyte models for the prediction of late normal tissue responses in breast radiotherapy patients. Poster presenter, 2013 ASCO Annual Meeting, Chicago & ASTRO 55th Annual Meeting 2013, Atlanta
70. **Chua ML**, Rothkamm K. **DNA double-strand break repair and induction of apoptosis in relation to late normal tissue responses following radiotherapy for early breast cancer. Oral and Poster presenter, The Joint International Symposium on EPR Dosimetry and Dating and the International Conference on Biological Dosimetry 2013, Leiden**
71. **Chua ML**, et al. **DNA double-strand break repair and induction of apoptosis in relation to late normal tissue responses following radiotherapy for early breast cancer. Oral presenter, ASTRO 54th Annual Meeting 2012, Boston**
72. **Chua ML**, et al. DNA damage responses in relation to late effects following radiotherapy for early breast cancer. Poster presenter, ASCO Annual Meeting 2012, Chicago
73. **Chua ML**, et al. DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes of breast cancer patients. Poster presenter, ESTRO 31 2012, Barcelona

74. **Chua ML**, et al. Radiation responses in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. Poster presenter, 14th International Congress of Radiation Research 2011, Warsaw
75. **Chua ML**, et al. **Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. Poster presenter, 12th Wolfsberg International Meeting 2011, Ermatingen**
76. **Chua ML**, et al. Residual DNA damage in different cell types and patients after in vivo irradiation of human skin. Poster presenter, 1st BIR scientist-in-training meeting 2010, London & ESTRO 29 2010, Barcelona
77. **Chua ML**, et al. Central Nervous System Metastasis in Endemic Nasopharyngeal Carcinoma: A Retrospective Institutional Review. Poster presenter, 95th RSNA 2009, Chicago
78. **Chua ML**, et al. In-vitro interaction of cyclooxygenase-2 (COX-2) inhibitors with radiation in nasopharyngeal carcinoma: dependent on sequence of administration. Poster presenter, 2nd World Congress of International Association of Oral Oncology 2009, Toronto
79. **Chua ML**, et al. **Comparison of three modalities for skull base invasion in nasopharyngeal carcinoma. Oral presenter, 14th Asean Association of Radiology Meeting 2008, Hanoi**
80. **Chua ML**, et al. **Comparison of the efficacy of PET/CT, conventional CT, and MRI in detecting intra-cranial extension of nasopharyngeal carcinoma. Oral presenter, 12th Asian Oceanian Society of Radiology Annual Meeting 2008, Seoul**
81. **Chua ML**, et al. **Comparison of four different modalities for distant metastases staging in endemic nasopharyngeal carcinoma. Oral presenter, 17th Singapore Radiological Society Annual Meeting 2008, Singapore & Poster presenter, 49th ASTRO Annual Meeting 2007, Los Angeles**